EP2387614A2 - Method for the production of glutaconate - Google Patents
Method for the production of glutaconateInfo
- Publication number
- EP2387614A2 EP2387614A2 EP10700416A EP10700416A EP2387614A2 EP 2387614 A2 EP2387614 A2 EP 2387614A2 EP 10700416 A EP10700416 A EP 10700416A EP 10700416 A EP10700416 A EP 10700416A EP 2387614 A2 EP2387614 A2 EP 2387614A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- sequences
- coa
- recombinant
- glutaconate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 94
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 title claims description 56
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 90
- 230000014509 gene expression Effects 0.000 claims abstract description 49
- 244000005700 microbiome Species 0.000 claims abstract description 45
- 239000013598 vector Substances 0.000 claims abstract description 36
- 108010087331 glutaconate CoA-transferase Proteins 0.000 claims abstract description 28
- 108010006027 2-hydroxyglutaryl-CoA dehydratase Proteins 0.000 claims abstract description 23
- 150000001991 dicarboxylic acids Chemical class 0.000 claims abstract description 14
- 230000002210 biocatalytic effect Effects 0.000 claims abstract description 10
- 239000004952 Polyamide Substances 0.000 claims abstract description 7
- 229920002647 polyamide Polymers 0.000 claims abstract description 7
- 229920000728 polyester Polymers 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 103
- 102000004190 Enzymes Human genes 0.000 claims description 73
- 108090000790 Enzymes Proteins 0.000 claims description 73
- 150000001875 compounds Chemical class 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- -1 unsaturated dicarboxylic acid compound Chemical class 0.000 claims description 43
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 241000604450 Acidaminococcus fermentans Species 0.000 claims description 23
- 108010057379 2-hydroxyglutarate dehydrogenase Proteins 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 102100020920 L-2-hydroxyglutarate dehydrogenase, mitochondrial Human genes 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 230000001105 regulatory effect Effects 0.000 claims description 20
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 18
- 239000012190 activator Substances 0.000 claims description 18
- 229930195712 glutamate Natural products 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 241000193450 [Clostridium] symbiosum Species 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 108091006088 activator proteins Proteins 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 229920000768 polyamine Polymers 0.000 claims description 7
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 6
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims description 6
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000005516 coenzyme A Substances 0.000 claims description 6
- 229940093530 coenzyme a Drugs 0.000 claims description 6
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 230000000379 polymerizing effect Effects 0.000 claims description 6
- 108700010070 Codon Usage Proteins 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 241000588722 Escherichia Species 0.000 claims description 4
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 238000005984 hydrogenation reaction Methods 0.000 claims description 3
- 241000604451 Acidaminococcus Species 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 241000605909 Fusobacterium Species 0.000 claims description 2
- 241000192013 Peptoniphilus asaccharolyticus Species 0.000 claims description 2
- 241000191992 Peptostreptococcus Species 0.000 claims description 2
- 241000186586 [Clostridium] sporosphaeroides Species 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 abstract description 55
- 102000039446 nucleic acids Human genes 0.000 abstract description 55
- 235000018102 proteins Nutrition 0.000 description 40
- 230000000694 effects Effects 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000009396 hybridization Methods 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 108090001042 Hydro-Lyases Proteins 0.000 description 15
- 102000004867 Hydro-Lyases Human genes 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000003999 initiator Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 8
- 238000010369 molecular cloning Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 150000002763 monocarboxylic acids Chemical class 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 101100070614 Acidaminococcus fermentans (strain ATCC 25085 / DSM 20731 / CCUG 9996 / CIP 106432 / VR4) hgdC gene Proteins 0.000 description 5
- 101100070615 Acidaminococcus fermentans (strain ATCC 25085 / DSM 20731 / CCUG 9996 / CIP 106432 / VR4) hgdH gene Proteins 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 238000012262 fermentative production Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- ITRSBJZNLOYNNR-WZZMXTMRSA-N (R)-2-hydroxyglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)[C@H](O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ITRSBJZNLOYNNR-WZZMXTMRSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- 241000672609 Escherichia coli BL21 Species 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000007505 standard i medium Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- URTLOTISFJPPOU-DEGQQWIJSA-N trans-4-carboxybut-2-enoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)\C=C\CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 URTLOTISFJPPOU-DEGQQWIJSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- HWXBTNAVRSUOJR-GSVOUGTGSA-N (R)-2-hydroxyglutaric acid Chemical compound OC(=O)[C@H](O)CCC(O)=O HWXBTNAVRSUOJR-GSVOUGTGSA-N 0.000 description 3
- ITRSBJZNLOYNNR-RMNRSTNRSA-N 2-hydroxyglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ITRSBJZNLOYNNR-RMNRSTNRSA-N 0.000 description 3
- FGSBNBBHOZHUBO-UHFFFAOYSA-N 2-oxoadipic acid Chemical compound OC(=O)CCCC(=O)C(O)=O FGSBNBBHOZHUBO-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DZNDBGBQXVQBCM-MXYRDGFCSA-N (5r)-6-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-5-hydroxy-6-oxohexanoic acid Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)[C@H](O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 DZNDBGBQXVQBCM-MXYRDGFCSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 description 2
- AFFLGGQVNFXPEV-UHFFFAOYSA-N 1-decene Chemical compound CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 2
- CRSBERNSMYQZNG-UHFFFAOYSA-N 1-dodecene Chemical compound CCCCCCCCCCC=C CRSBERNSMYQZNG-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical class [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108010068207 Glutaconyl-CoA decarboxylase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000000746 allylic group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- 238000002742 combinatorial mutagenesis Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 101150081465 hgdH gene Proteins 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- JBEBGTMCZIGUTK-TZFCGSKZSA-N (2Z,4E)-2-hydroxymuconic acid Chemical compound OC(=O)\C=C\C=C(/O)C(O)=O JBEBGTMCZIGUTK-TZFCGSKZSA-N 0.000 description 1
- YCDKGDLJLWZHKA-UHFFFAOYSA-N (5-amino-4-methyl-5-oxopent-3-enyl)-trimethylazanium chloride Chemical compound [Cl-].NC(=O)C(C)=CCC[N+](C)(C)C YCDKGDLJLWZHKA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 101710139295 (R)-2-hydroxyglutarate dehydrogenase Proteins 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- LGXVIGDEPROXKC-UHFFFAOYSA-N 1,1-dichloroethene Chemical compound ClC(Cl)=C LGXVIGDEPROXKC-UHFFFAOYSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- BVCPHGJYVNRFRP-UHFFFAOYSA-N 1-ethenyl-1-methylimidazol-1-ium Chemical class C=C[N+]1(C)C=CN=C1 BVCPHGJYVNRFRP-UHFFFAOYSA-N 0.000 description 1
- JWYVGKFDLWWQJX-UHFFFAOYSA-N 1-ethenylazepan-2-one Chemical compound C=CN1CCCCCC1=O JWYVGKFDLWWQJX-UHFFFAOYSA-N 0.000 description 1
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BQMWZHUIGYNOAL-UHFFFAOYSA-N 1-phenylethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)C1=CC=CC=C1 BQMWZHUIGYNOAL-UHFFFAOYSA-N 0.000 description 1
- CXKZIYUKNUMIBO-UHFFFAOYSA-N 1-phenylethyl prop-2-enoate Chemical compound C=CC(=O)OC(C)C1=CC=CC=C1 CXKZIYUKNUMIBO-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 description 1
- XNQDKIWPZVPVQD-UHFFFAOYSA-N 2-(2-methylprop-2-enoylamino)ethanesulfonic acid Chemical compound CC(=C)C(=O)NCCS(O)(=O)=O XNQDKIWPZVPVQD-UHFFFAOYSA-N 0.000 description 1
- PRAMZQXXPOLCIY-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethanesulfonic acid Chemical compound CC(=C)C(=O)OCCS(O)(=O)=O PRAMZQXXPOLCIY-UHFFFAOYSA-N 0.000 description 1
- JBIUHXCCAZFBCL-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(C)OC(=O)C(C)=C JBIUHXCCAZFBCL-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 1
- UVDYBBRVDUKNFV-UHFFFAOYSA-N 2-(prop-2-enoylamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCNC(=O)C=C UVDYBBRVDUKNFV-UHFFFAOYSA-N 0.000 description 1
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- DZNDBGBQXVQBCM-XMWLYHNJSA-N 2-hydroxyadipoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 DZNDBGBQXVQBCM-XMWLYHNJSA-N 0.000 description 1
- IEVADDDOVGMCSI-UHFFFAOYSA-N 2-hydroxybutyl 2-methylprop-2-enoate Chemical compound CCC(O)COC(=O)C(C)=C IEVADDDOVGMCSI-UHFFFAOYSA-N 0.000 description 1
- NJRHMGPRPPEGQL-UHFFFAOYSA-N 2-hydroxybutyl prop-2-enoate Chemical compound CCC(O)COC(=O)C=C NJRHMGPRPPEGQL-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
- GWZMWHWAWHPNHN-UHFFFAOYSA-N 2-hydroxypropyl prop-2-enoate Chemical compound CC(O)COC(=O)C=C GWZMWHWAWHPNHN-UHFFFAOYSA-N 0.000 description 1
- VSSGDAWBDKMCMI-UHFFFAOYSA-N 2-methyl-2-(2-methylprop-2-enoylamino)propane-1-sulfonic acid Chemical compound CC(=C)C(=O)NC(C)(C)CS(O)(=O)=O VSSGDAWBDKMCMI-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- XEEYSDHEOQHCDA-UHFFFAOYSA-N 2-methylprop-2-ene-1-sulfonic acid Chemical compound CC(=C)CS(O)(=O)=O XEEYSDHEOQHCDA-UHFFFAOYSA-N 0.000 description 1
- RUMACXVDVNRZJZ-UHFFFAOYSA-N 2-methylpropyl 2-methylprop-2-enoate Chemical compound CC(C)COC(=O)C(C)=C RUMACXVDVNRZJZ-UHFFFAOYSA-N 0.000 description 1
- CFVWNXQPGQOHRJ-UHFFFAOYSA-N 2-methylpropyl prop-2-enoate Chemical compound CC(C)COC(=O)C=C CFVWNXQPGQOHRJ-UHFFFAOYSA-N 0.000 description 1
- CEXQWAAGPPNOQF-UHFFFAOYSA-N 2-phenoxyethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOC1=CC=CC=C1 CEXQWAAGPPNOQF-UHFFFAOYSA-N 0.000 description 1
- RZVINYQDSSQUKO-UHFFFAOYSA-N 2-phenoxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC1=CC=CC=C1 RZVINYQDSSQUKO-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- ILZXXGLGJZQLTR-UHFFFAOYSA-N 2-phenylethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC1=CC=CC=C1 ILZXXGLGJZQLTR-UHFFFAOYSA-N 0.000 description 1
- HPSGLFKWHYAKSF-UHFFFAOYSA-N 2-phenylethyl prop-2-enoate Chemical compound C=CC(=O)OCCC1=CC=CC=C1 HPSGLFKWHYAKSF-UHFFFAOYSA-N 0.000 description 1
- GQTFHSAAODFMHB-UHFFFAOYSA-N 2-prop-2-enoyloxyethanesulfonic acid Chemical compound OS(=O)(=O)CCOC(=O)C=C GQTFHSAAODFMHB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical class C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- ZAXCZCOUDLENMH-UHFFFAOYSA-N 3,3,3-tetramine Chemical compound NCCCNCCCNCCCN ZAXCZCOUDLENMH-UHFFFAOYSA-N 0.000 description 1
- DXIJHCSGLOHNES-UHFFFAOYSA-N 3,3-dimethylbut-1-enylbenzene Chemical compound CC(C)(C)C=CC1=CC=CC=C1 DXIJHCSGLOHNES-UHFFFAOYSA-N 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- IZGYLHCAIASIFV-UHFFFAOYSA-N 3-carbamoylbut-3-enyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCC(=C)C(N)=O IZGYLHCAIASIFV-UHFFFAOYSA-N 0.000 description 1
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OFNISBHGPNMTMS-UHFFFAOYSA-N 3-methylideneoxolane-2,5-dione Chemical compound C=C1CC(=O)OC1=O OFNISBHGPNMTMS-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- NYUTUWAFOUJLKI-UHFFFAOYSA-N 3-prop-2-enoyloxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC(=O)C=C NYUTUWAFOUJLKI-UHFFFAOYSA-N 0.000 description 1
- UYAFNMBGMXYWSZ-UHFFFAOYSA-N 4-(dimethylamino)-2-methylidenebutanamide Chemical compound CN(C)CCC(=C)C(N)=O UYAFNMBGMXYWSZ-UHFFFAOYSA-N 0.000 description 1
- YYWNXJKMAJYRSP-UHFFFAOYSA-N 4-carbamoylpent-4-enyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCC(=C)C(N)=O YYWNXJKMAJYRSP-UHFFFAOYSA-N 0.000 description 1
- YKXAYLPDMSGWEV-UHFFFAOYSA-N 4-hydroxybutyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCO YKXAYLPDMSGWEV-UHFFFAOYSA-N 0.000 description 1
- NDWUBGAGUCISDV-UHFFFAOYSA-N 4-hydroxybutyl prop-2-enoate Chemical compound OCCCCOC(=O)C=C NDWUBGAGUCISDV-UHFFFAOYSA-N 0.000 description 1
- ZWAPMFBHEQZLGK-UHFFFAOYSA-N 5-(dimethylamino)-2-methylidenepentanamide Chemical compound CN(C)CCCC(=C)C(N)=O ZWAPMFBHEQZLGK-UHFFFAOYSA-N 0.000 description 1
- LVGSUQNJVOIUIW-UHFFFAOYSA-N 5-(dimethylamino)-2-methylpent-2-enamide Chemical compound CN(C)CCC=C(C)C(N)=O LVGSUQNJVOIUIW-UHFFFAOYSA-N 0.000 description 1
- OOEDHTCVMHDXRH-UHFFFAOYSA-N 5-oxohex-2-enedioic acid Chemical compound OC(=O)C=CCC(=O)C(O)=O OOEDHTCVMHDXRH-UHFFFAOYSA-N 0.000 description 1
- FLCAEMBIQVZWIF-UHFFFAOYSA-N 6-(dimethylamino)-2-methylhex-2-enamide Chemical compound CN(C)CCCC=C(C)C(N)=O FLCAEMBIQVZWIF-UHFFFAOYSA-N 0.000 description 1
- JTHZUSWLNCPZLX-UHFFFAOYSA-N 6-fluoro-3-methyl-2h-indazole Chemical compound FC1=CC=C2C(C)=NNC2=C1 JTHZUSWLNCPZLX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100070613 Acidaminococcus fermentans (strain ATCC 25085 / DSM 20731 / CCUG 9996 / CIP 106432 / VR4) hgdB gene Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 1
- 102000006732 Citrate synthase Human genes 0.000 description 1
- 101100506210 Clostridioides difficile hadC gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010077385 Coenzyme A-Transferases Proteins 0.000 description 1
- 102000010079 Coenzyme A-Transferases Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 108091000109 Crotonyl-CoA carboxylase/reductase Proteins 0.000 description 1
- YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010001539 D-lactate dehydrogenase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102100023319 Dihydrolipoyl dehydrogenase, mitochondrial Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001183197 Fusobacteriales Species 0.000 description 1
- 241001291923 Fusobacterium nucleatum subsp. nucleatum Species 0.000 description 1
- 241001408548 Fusobacterium nucleatum subsp. nucleatum ATCC 25586 Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108700006770 Glutaric Acidemia I Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- WSDOHRLQDGAOGU-BQBZGAKWSA-N His-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 WSDOHRLQDGAOGU-BQBZGAKWSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101150032986 Lar gene Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical class [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 239000004228 Riboflavin-5'-Phosphate Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- VMDMOKQDJAFRDO-CITAKDKDSA-N S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 4-nitrobut-2-enethioate Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C=CC[N+]([O-])=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VMDMOKQDJAFRDO-CITAKDKDSA-N 0.000 description 1
- WUNOSVWMPVCDKM-HDRQGHTBSA-N S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 4-oxohex-2-enethioate Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C=CC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUNOSVWMPVCDKM-HDRQGHTBSA-N 0.000 description 1
- 229910003798 SPO2 Inorganic materials 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- TYYLDKGBCJGJGW-WMZOPIPTSA-N Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=C(O)C=C1 TYYLDKGBCJGJGW-WMZOPIPTSA-N 0.000 description 1
- BMPPMAOOKQJYIP-WMZOPIPTSA-N Tyr-Trp Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C([O-])=O)C1=CC=C(O)C=C1 BMPPMAOOKQJYIP-WMZOPIPTSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NJSSICCENMLTKO-HRCBOCMUSA-N [(1r,2s,4r,5r)-3-hydroxy-4-(4-methylphenyl)sulfonyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1C(O)[C@@H](OS(=O)(=O)C=2C=CC(C)=CC=2)[C@@H]2OC[C@H]1O2 NJSSICCENMLTKO-HRCBOCMUSA-N 0.000 description 1
- RYTFZTUAFHWACC-UHFFFAOYSA-N [Cl-].NC(=O)C(C)=CCCC[N+](C)(C)C Chemical compound [Cl-].NC(=O)C(C)=CCCC[N+](C)(C)C RYTFZTUAFHWACC-UHFFFAOYSA-N 0.000 description 1
- YEDTWOLJNQYBPU-UHFFFAOYSA-N [Na].[Na].[Na] Chemical compound [Na].[Na].[Na] YEDTWOLJNQYBPU-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- AOJOEFVRHOZDFN-UHFFFAOYSA-N benzyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC1=CC=CC=C1 AOJOEFVRHOZDFN-UHFFFAOYSA-N 0.000 description 1
- GCTPMLUUWLLESL-UHFFFAOYSA-N benzyl prop-2-enoate Chemical compound C=CC(=O)OCC1=CC=CC=C1 GCTPMLUUWLLESL-UHFFFAOYSA-N 0.000 description 1
- RTGHRDFWYQHVFW-UHFFFAOYSA-N beta-Ketoadipic acid Natural products OC(=O)CCC(=O)CC(O)=O RTGHRDFWYQHVFW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 238000013452 biotechnological production Methods 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- PVEOYINWKBTPIZ-UHFFFAOYSA-N but-3-enoic acid Chemical compound OC(=O)CC=C PVEOYINWKBTPIZ-UHFFFAOYSA-N 0.000 description 1
- VXTQKJXIZHSXBY-UHFFFAOYSA-N butan-2-yl 2-methylprop-2-enoate Chemical compound CCC(C)OC(=O)C(C)=C VXTQKJXIZHSXBY-UHFFFAOYSA-N 0.000 description 1
- RNOOHTVUSNIPCJ-UHFFFAOYSA-N butan-2-yl prop-2-enoate Chemical compound CCC(C)OC(=O)C=C RNOOHTVUSNIPCJ-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000010941 cobalt Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical class [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- KFWWCMJSYSSPSK-PAXLJYGASA-N crotonoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)/C=C/C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 KFWWCMJSYSSPSK-PAXLJYGASA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- OIWOHHBRDFKZNC-UHFFFAOYSA-N cyclohexyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC1CCCCC1 OIWOHHBRDFKZNC-UHFFFAOYSA-N 0.000 description 1
- KBLWLMPSVYBVDK-UHFFFAOYSA-N cyclohexyl prop-2-enoate Chemical compound C=CC(=O)OC1CCCCC1 KBLWLMPSVYBVDK-UHFFFAOYSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- GTBGXKPAKVYEKJ-UHFFFAOYSA-N decyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C(C)=C GTBGXKPAKVYEKJ-UHFFFAOYSA-N 0.000 description 1
- FWLDHHJLVGRRHD-UHFFFAOYSA-N decyl prop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C=C FWLDHHJLVGRRHD-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- JBSLOWBPDRZSMB-BQYQJAHWSA-N dibutyl (e)-but-2-enedioate Chemical compound CCCCOC(=O)\C=C\C(=O)OCCCC JBSLOWBPDRZSMB-BQYQJAHWSA-N 0.000 description 1
- JBSLOWBPDRZSMB-FPLPWBNLSA-N dibutyl (z)-but-2-enedioate Chemical compound CCCCOC(=O)\C=C/C(=O)OCCCC JBSLOWBPDRZSMB-FPLPWBNLSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- IEPRKVQEAMIZSS-AATRIKPKSA-N diethyl fumarate Chemical compound CCOC(=O)\C=C\C(=O)OCC IEPRKVQEAMIZSS-AATRIKPKSA-N 0.000 description 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- LDCRTTXIJACKKU-ARJAWSKDSA-N dimethyl maleate Chemical compound COC(=O)\C=C/C(=O)OC LDCRTTXIJACKKU-ARJAWSKDSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940069096 dodecene Drugs 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical compound CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 description 1
- GLVVKKSPKXTQRB-UHFFFAOYSA-N ethenyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC=C GLVVKKSPKXTQRB-UHFFFAOYSA-N 0.000 description 1
- LZWYWAIOTBEZFN-UHFFFAOYSA-N ethenyl hexanoate Chemical compound CCCCCC(=O)OC=C LZWYWAIOTBEZFN-UHFFFAOYSA-N 0.000 description 1
- AFSIMBWBBOJPJG-UHFFFAOYSA-N ethenyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC=C AFSIMBWBBOJPJG-UHFFFAOYSA-N 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- XUCNUKMRBVNAPB-UHFFFAOYSA-N fluoroethene Chemical compound FC=C XUCNUKMRBVNAPB-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 208000005461 glutaric acidemia I Diseases 0.000 description 1
- 150000002311 glutaric acids Chemical class 0.000 description 1
- SYKWLIJQEHRDNH-CKRMAKSASA-N glutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SYKWLIJQEHRDNH-CKRMAKSASA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical class OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000005451 methyl sulfates Chemical class 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- DTSDBGVDESRKKD-UHFFFAOYSA-N n'-(2-aminoethyl)propane-1,3-diamine Chemical compound NCCCNCCN DTSDBGVDESRKKD-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- WDQKICIMIPUDBL-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]prop-2-enamide Chemical compound CN(C)CCNC(=O)C=C WDQKICIMIPUDBL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- HMZGPNHSPWNGEP-UHFFFAOYSA-N octadecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(C)=C HMZGPNHSPWNGEP-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- UIIIBRHUICCMAI-UHFFFAOYSA-N prop-2-ene-1-sulfonic acid Chemical compound OS(=O)(=O)CC=C UIIIBRHUICCMAI-UHFFFAOYSA-N 0.000 description 1
- ARJOQCYCJMAIFR-UHFFFAOYSA-N prop-2-enoyl prop-2-enoate Chemical compound C=CC(=O)OC(=O)C=C ARJOQCYCJMAIFR-UHFFFAOYSA-N 0.000 description 1
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical class OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000006250 specific catalysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 101150038671 strat gene Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- SJMYWORNLPSJQO-UHFFFAOYSA-N tert-butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)(C)C SJMYWORNLPSJQO-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- FAGUFWYHJQFNRV-UHFFFAOYSA-N tetraethylenepentamine Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- HSBSUGYTMJWPAX-HNQUOIGGSA-N trans-2-hexenedioic acid Chemical compound OC(=O)CC\C=C\C(O)=O HSBSUGYTMJWPAX-HNQUOIGGSA-N 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000003597 transferase activity assay Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001124 trientine Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- FZGFBJMPSHGTRQ-UHFFFAOYSA-M trimethyl(2-prop-2-enoyloxyethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCOC(=O)C=C FZGFBJMPSHGTRQ-UHFFFAOYSA-M 0.000 description 1
- RRHXZLALVWBDKH-UHFFFAOYSA-M trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CC(=C)C(=O)OCC[N+](C)(C)C RRHXZLALVWBDKH-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- VLRGDRPJPYAIMX-UHFFFAOYSA-L zinc pent-2-enedioate Chemical compound [Zn++].[O-]C(=O)CC=CC([O-])=O VLRGDRPJPYAIMX-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/50—Polycarboxylic acids having keto groups, e.g. 2-ketoglutaric acid
Definitions
- the present invention relates to a novel method for the biocatalytic production of unsaturated dicarboxylic acids by cultivating a recombinant microorganism co-expressing a glutaconate CoA-transferase and a 2-hydroxyglutaryl-CoA dehydratase system.
- the present invention also relates to corresponding recombinant hosts, recombinant vectors, expression cassettes and nucleic acids suitable for preparing such hosts as well as a method of preparing polymers, as for example polyamide or polyester copolymers, making use of said dicarboxylic acids as obtained by said biocatalytic production method.
- Glutaconic acid is an ⁇ , ⁇ -unsaturated C5-dicarboxylic acid (2-pentenedioic acid) that accumulates in individuals with glutaric acidemia type I (Hoffmann GF, Zschocke J (1999) Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy. J Inherit Metab Dis 22:381-391). Glutaconic acid together with a diamine can polymerize to a polyamide related to Nylon®. The ideal material for biotechnological production of glutaconic acid would be glutamic acid, which can be produced by sugar fermentation. The chemical deamination of ⁇ -amino acids to ⁇ , ⁇ - unsaturated acids is very difficult.
- Acidaminococcus fermentans and Clostridium symbiosum can easily deaminate glutamate via ⁇ -ketoglutarate, (R)-2-hydroxyglutarate, (R)-2-hydroxyglutaryl-CoA, and glutaconyl-CoA to (£)-glutaconate (Buckel W (2001b) Unusual enzymes involved in five pathways of glutamate fermentation. Appl Microbiol Biotechnol 57:263-273).
- A. fermentans and C. symbiosum are not suitable for the production of glutaconic acid because they decarboxylate glutaconyl-CoA to crotonyl-CoA. Genetic manipulation of these organisms has not been established yet.
- the object of the present invention is therefore to provide a suitable method for the fermentative, biocatalytic production of glutaconic acid and related dicarboxylic acids or corresponding salts thereof.
- Figure 1 depicts the pathway for glutaconate production.
- the enzymes of the final steps are numbered with 1 , 2 and 3.
- 1 2-hydroxyglutarate dehydrogenase
- 2 glutaconate CoA-transferase
- 3 2-hydroxyglutaryl-CoA dehydratase.
- Figure 2 depicts schematically the construction of recombinant plasmid pACYCDuet-1 (Fig. 2A) in which the coding sequences for 2-hydroxyglutarate dehydrogenase (hgdH) and glutaconate CoA-transferase (gctAB), (subunits A and B) are inserted (Fig. 2B).
- Figure 3 depicts schematically the construction of recombinant plasmids pASK- IBA3plus (Fig. 3A) in which the coding sequences for 2-hydroxyglutaryl-CoA dehydratase (subunits hdgA and hgdB) and its activator (hdgC) are inserted (Fig. 3B).
- the above-mentioned problem was solved by the present invention teaching a biocatalytic method for the production of an unsaturated dicarboxylic acid compound , like glutaconate or a structurally similar glutaconate compound (of formula I) which method comprises converting a corresponding 2-hydroxy-substituted dicarboxylic acid in a recombinant microorganism co-expressing a glutaconate CoA-transferase and a 2- hydroxyglutaryl-CoA dehydratase system, so that said unsaturated dicarboxylic acid is formed
- the present inventors expressed six genes, encoding 2-hydroxyglutarate dehydrogenase (HgdA, 1 in Fig. 1 ), glutaconate CoA-transferase (GcdAB, 2), 2-hydroxyglutaryl-CoA dehydratase (HgdAB, 3) and its activator (HgdC, 3).
- the new pathway can divert at ⁇ - ketoglutarate derived from glucose via the Embden-Meyerhof pathway and the citrate cycle.
- HOOC-CH CH-X-COOH (I) in particular the E-form of such a compound; wherein X represents a linear or branched, optionally unsaturated, optionally substituted hydrocarbon group, preferably having 1 , 2, 3 or 4 carbon atoms;
- CoA coenzyme A
- acyl-CoA like C 2 -C 6 -acyl-CoA
- acetyl- coenzyme A which CoA source may be of any origin, like endogenic to said micoroorganism,. i.e. produced by said microorganism, or exogenic, i.e.
- said 2-hydroxy-substituted dicarboxylic acid III is preferably formed by said recombinant microorganism in a 2-hydroxyglutarate dehydrogenase (E. C. 1.1.1.-) catalyzed conversion of a 2-oxo-dicarboxylic acid compound of formula Il
- said oxo-dicarboxylic acid compound of formula Il is either added to or fermentatively produced by said recombinant microorganism.
- the method of the invention comprises the cultivation of at least one recombinant microorganism, which microorganism is derived from a parent microorganism having the ability to produce said 2-oxo-dicarboxylic acid compound of formula Il as intermediary product of a metabolic pathway, and additionally having the ability to express heterologously at least one of the above mentioned enzymes and proteins.
- said microorganism is a glutamate and/or glucose metabolizing aerobic or anaerobic recombinant bacterium
- said compound of formula Il is 2- oxoglutarate formed by the biodegradation of glutamate (for example by the action of glutamate dehydrogenase) and/or glucose (for example via the Embden-Meyerhof pathway and the Krebs or citric acid cycle).
- individual enzymes involved in said glutamate or glucose metabolism may be deregulated in order to further assist, or improve the formation of the intended product and/or to reduce or avoid the formation of undesired side products or secondary products (formed by the metabolization of the intended product) which otherwise would lessen or decrease the actual amount or concentration of the intended product as formed by the microrganism .
- said glutamate and/or glucose metabolizing recombinant bacterium is selected from bacteria of the genus Escherichia, as for example E. coli, like the strain E. coli BL21-CodonPlus® (DE3)-RIL strain (Stratgene).
- the CodonPlus plasmid responsible for chloramphenicol resistance may also be removed.
- CoA dehydratase system comprises a 2-hydroxyglutaryl-CoA dehydratase (E. C. 4.2.1.) and, if required for inducing and/or maintaining the intended dehydratase activity, optionally an activator protein for said enzyme.
- Said activator protein may be required for establishing dehydratase activity.
- said enzymes and proteins are of prokaryotic or eukaryotic origin. In particular they may originate from different microbial genera or strains.
- dehydratase and the activator for establishing dehydratase activity are derived from the same microbial genus or strain as long as the activator cooperates with (activates the) dehydratase enzyme as used for the bioconversion reaction.
- said enzymes and activator originate from the same or different anaerobic bacterium, which bacterium being able to convert glutamate into glutaconate.
- said anaerobic bacterium is selected from bacteria of the genus Acidaminococcus, Clostridium, Fusobacterium or Peptostreptococcus, in particular Acidaminococcus fermentans, Clostridium symbiosum, Clostridium sporosphaeroides, Fusobacterium nucleatum including all subspecies, or Peptostreptococcus asaccharolyticus.
- said 2-hydroxyglutarate dehydrogenase comprises at least one amino acid sequence of SEQ I D NO: 1 6 (FN0487, annotated as D-lactate dehydrogenase - Fusobacterium nucleatum subsp. nucleatum ATCC 25586; GenelD: 991766) or SEQ ID NO:2 (1XDW_A ⁇ A. fermentans); or a sequence having at least 50% identity to at least one of said sequences, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity, and still retaining the intended enzyme activity (or function), i.e.
- HgdH enzyme being applicable as HgdH enzyme; for example said enzyme may be a homodimer, as for example the A. fermentans enzyme; for example the A. fermentans enzyme shows 61 % sequence identity to the enzyme from F. nucleatum. I n particular, said glutaconate CoA transferase (GctAB), which may be a heterooctamer ( ⁇ 4 ⁇ 4 )
- (a) comprises at least one alpha (A) and at least one beta (B) subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 4 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 6 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e.
- (b) comprises at least one alpha and at least one beta subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 22 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 24 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as GctAB enzyme; or
- (c) comprises at least one alpha and at least one beta subunit, wherein said alpha subunit comprising an amino acid sequence accord ing to S EQ I D NO : 1 8 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 20 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as GctAB enzyme.
- said 2-hydroxyglutaryl-CoA dehydratase which may be a heterodimer (AB) or trimer (ABD) with one [4Fe-4S] cluster in each A and each B subunit, and (a) comprises at least one alpha (A) and at least one beta (B) subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 26 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 28 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as dehydratase enzyme; or
- (b) comprises at least one alpha (A), at least one beta (B) subunit and at least one delta (D) subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 30 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 32 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said gamma subunit comprising an amino acid sequence according to SEQ ID NO: 34 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e.
- (c) comprises at least one alpha and at least one beta subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 8 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 10 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as dehydratase enzyme.
- said the activator protein comprises at least one amino acid sequence of SEQ ID NO: 12, 36 or 38 or a sequence having at least 50% identity to at least one of said sequences as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended activity, i.e. being applicable as dehydratase activator; an may be a homodimer with one [4Fe-4S] cluster between the two subunits.
- said 2-hydroxyglutaryl-CoA dehydratase is from C. symbiosum (S EQ I D NO : 8 and/or 10); while said 2-hydroxyglutarate dehydrogenase (SEQ ID NO:2); said glutaconate CoA transferase (SEQ ID NO:4 and/or 6) and said activator protein (SEQ ID NO:12) are from A. fermentans; or independently of each other being derived there form, and having a sequence of at least 50% identity to the parent sequence, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme or activator activity.
- Said proteins may be present in the form of the active quaternary structure or may be present in the form of active fragments or subunits thereof.
- said proteins and enzymes may each be encoded by a nucleic acid sequence, which is adapted to the codon usage of said microorganism having the ability to produce said 2-oxo-dicarboxylic acid of formula II.
- said proteins and enzymes may be encoded by nucleic acid sequences contained in one single or more expression vectors in may be encoded as single or multiple copies. Additionally, at least one of said co-expressed proteins is heterologous to said recombinant microorganism.
- the present invention also relates to : an expression cassette, comprising a combination of at least two different nucleic acid sequences encoding an enzyme or protein as defined above
- sequences are operatively linked to at least one regulatory nucleic acid sequence; - a recombinant vector, comprising at least one of said expression cassettes; a recombinant prokaryotic or eukaryotic host, transformed with at least one such vector.
- Such recombinant hosts have the ability to produce a 2-oxo- dicarboxylic acid compound of formula (II), which is converted to a compound of formula (I) upon expression of said expression products as encoded by said at least one vector.
- said host may be a recombinant strain of a bacterium of the genus Escherichia.
- said polyamine is a di-amine, a tri-amine or a mixture thereof and said polyvalent hydroxyl compound is a diol or triol or a mixture thereof.
- said polymerization reaction may be performed in the presence of a suitable catalyst, as for example acid or base catalyst.
- the present invention relates to a method of preparing a polymer, which method comprises a) preparing a mono-unsaturated dicarboxylic acid compounds of the general formula (I) as defined above a by method as defined above; b) isolating said compound; and c) polymerizing said compound as obtained according to step b), with at least one suitable unsaturated polymerizable monomer.
- said polymerization may be performed in the presence of a suitable radical initiator.
- at least one gene, as for example 1 , 2, 3 or 4 genes, of a biosynthetic pathway in said recombinant microorganism directly or indirectly affecting the formation and/or decomposition of at least one compound of formula (I), (II) or (III), may deregulated (up or down regulated) in order to further optimize the method of the invention.
- glutaconate and “glutaconic acid” or the expressions “glutaconate compound” and “glutaconic acid compound” or the expressions “unsaturated dicarboxylic acid” or “unsaturated dicarboxylate compound” are considered to be synonymous.
- the glutaconate or dicarboxylic acid compound (of formula I) as obtained according to the present invention may be in the form of the free acid, in the form of a partial or complete salt of said acid or in the form of mixtures of the acid and its salt.
- a dicarboxylic acid "salt” comprises for example metal salts, as for example zinc glutaconate, mono- or di-alkalimetal salts of said acid, like mono-sodium di-sodium, mono-potassium and di-potassium salts as well as alkaline earth metal salts as for example the calcium or magnesium salts.
- biocatalytic method refers to any method performed in the presence of catalytic activity of an enzyme as defined herein, i.e. in the presence of isolated pure or crude enzyme or entire microbial cells containing or expression such enzyme activity.
- ,stereospecific means that one of several stereoisomers or enantiomers is formed by the enzyme in high enantiomeric excess or purity, of at least 90%ee, preferably at least 95 %ee, in particular at least 98 %ee, or at least 99 %ee.
- Examples of "stereoisomers” are E-and Z- isomers or R- and S enantiomers.
- “Deregulation” has to be understood in its broadest sense, and comprises an increase or decrease of complete switch off of an enzyme (target enzyme) activity by different means well known to those in the art. Suitable methods comprise for example an increase or decrease of the copy number of gene and /or enzyme molecules in an organism, or the modification of another feature of the enzyme affecting the its enzymatic activity, which then results in the desired effect on a metabolic pathway at issue, or any pathway or enzymatic reaction coupled thereto.
- Suitable genetic manipulation can also include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (e.g., by removing strong promoters, inducible promoters or multiple promoters), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particu lar gene such as a ribosome bind ing site or transcription terminator, decreasing the copy number of a particular gene, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules), or other methods to knock-out or block expression of the target protein.
- modifying proteins e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like
- a preferred way of an "amplification” is an "up"- mutation which increases the gene activity e.g. by gene amplification using strong expression signals and/or point mutations which enhance the enzymatic activity.
- a preferred way of an “attenuation” is a "down"- mutation which decreases the gene activity e.g. by gene deletion or disruption, using weak expression signals and/or point mutations which destroy or decrease the enzymatic activity.
- heterologous or “exogenous” refers to sequences as described herein, which are introduced into or produced (transcribed or translated) by a genetically manipulated microorganism as defined herein and which microorganism prior to said manipulation did not contain or did not produce said sequence.
- said microorganism prior to said manipulation may not contain or express said heterologous enzyme activity, or may contain or express an endogenous enzyme of comparable activity or specificity, which is encoded by a different coding sequence or by an enzyme of different amino acid sequence, and said endogenous enzyme may convert the same substrate or substrates as said exogenous enzyme.
- a "parent" microorganism of the present invention is any microorganism having the ability to produce a compound of formula (II) as intermediary product.
- An "intermediary product” is understood as a product, which is transiently or continuously formed during a chemical or biochemical process, in a not necessarily analytically directly detectable concentration. Said “intermediary product” may be removed from said biochemical process by a second, chemical or biochemical reaction.
- a “recombinant host” may be any prokaryotic or eukaryotic cell, which contains either a cloning vector or expression vector. This term is also meant to include those prokaryotic or eukaryotic cells that have been genetically engineered to contain the cloned gene(s) in the chromosome or genome of the host cell.
- suitable hosts see Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989).
- the term "recombinant microorganism” includes a microorganism (e.g., bacteria, yeast cell, fungal cell, etc.) which has been genetically altered, modified or engineered (e.g., genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (e.g., when the genetic modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism or "parent" microorganism which it was derived from.
- a microorganism e.g., bacteria, yeast cell, fungal cell, etc.
- modified or engineered e.g., genetically engineered
- a "substantially pure" protein or enzyme means that the desired purified protein is essentially free from contaminating cellular components, as evidenced by a single band following polyacrylamide-sodium dodecyl sulfate gel electrophoresis (SDS-PAGE).
- SDS-PAGE polyacrylamide-sodium dodecyl sulfate gel electrophoresis
- substantially pure is further meant to describe a molecu le, wh ich is homogeneous by one or more pu rity or homogeneity characteristics used by those of skill in the art.
- a substantially pure enzyme or protein will show constant and reproducible characteristics within standard experimental deviations for parameters such as the following: molecular mass, chromatographic migration, amino acid composition, amino acid sequence, blocked or unblocked N-terminus, H PLC elution profile, biological activity, and other such parameters.
- the term is not meant to exclude artificial or synthetic mixtures of said enzyme or protein with other compounds.
- the term is not meant to exclude fusion proteins optionally isolated from a recombinant host. 3.
- Further embodiments of the invention 3.1 Proteins according to the invention
- the present invention is not limited to the specifically mentioned enzymes/proteins, but also extends to functional equivalents thereof.
- “Functional equivalents” or “analogs” or “functional mutations” of the concretely disclosed enzymes are, within the scope of the present invention, various polypeptides thereof, which moreover possess the desired biological function or activity, e.g. enzyme activity.
- “functional equivalents” means enzymes, which, in a test used for enzymatic activity, display at least a 1 to 10%, or at least 20%, or at least 50%, or at least 75%, or at least 90% higher or lower activity of an enzyme, as defined herein.
- “Functional equivalents”, according to the invention also means in particular mutants, which, in at least one sequence position of the amino acid sequences stated above, have an amino acid that is different from that concretely stated, but nevertheless possess one of the aforementioned biological activities.
- “Functional equivalents” thus comprise the mutants obtainable by one or more amino acid additions, substitutions, deletions and/or inversions, where the stated changes can occur in any sequence position, provided they lead to a mutant with the profile of properties according to the invention.
- Functional equivalence is in particular also provided if the reactivity patterns coincide qualitatively between the mutant and the unchanged polypeptide, i.e. if for example the same substrates are converted at a different rate. Examples of suitable amino acid substitutions are shown in the following table:
- “Functional equivalents” in the above sense are also “precursors” of the polypeptides described, as well as “functional derivatives” and “salts” of the polypeptides. "Precursors” are in that case natural or synthetic precursors of the polypeptides with or without the desired biological activity.
- salts means salts of carboxyl groups as well as salts of acid addition of amino groups of the protein molecules according to the invention.
- Salts of carboxyl groups can be produced in a known way and comprise inorganic salts, for example sodium, calcium, ammonium, iron and zinc salts, and salts with organic bases, for example amines, such as triethanolamine, arginine, lysine, piperidine and the like.
- Salts of acid addition for example salts with inorganic acids, such as hydrochloric acid or sulfuric acid and salts with organic acids, such as acetic acid and oxalic acid, are also covered by the invention.
- “Functional derivatives” of polypeptides according to the invention can also be produced on functional amino acid side groups or at their N-terminal or C-terminal end using known techniques.
- Such derivatives comprise for example aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, obtainable by reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino groups, produced by reaction with acyl groups; or O-acyl derivatives of free hydroxy groups, produced by reaction with acyl groups.
- “Functional equivalents” naturally also comprise polypeptides that can be obtained from other organisms, as well as naturally occurring variants. For example, areas of homologous sequence regions can be established by sequence comparison, and equivalent enzymes can be determined on the basis of the concrete parameters of the invention.
- “Functional equivalents” also comprise fragments, preferably individual domains or sequence motifs, of the polypeptides according to the invention, which for example display the desired biological function.
- Fusion proteins are, moreover, fusion proteins, which have one of the polypeptide sequences stated above or functional equivalents derived there from and at least one further, functionally different, heterologous sequence in functional N- terminal or C-terminal association (i.e. without substantial mutual functional impairment of the fusion protein parts).
- heterologous sequences are e.g. signal peptides, histidine anchors or enzymes.
- “Functional equivalents” that are also included according to the invention are homologues of the concretely disclosed proteins. These possess percent identity values as stated above. Said values refer to the identity with the concretely disclosed amino acid sequences, and may be calculated according to the algorithm of Pearson and Lipman, Proc. Natl. Acad, Sci. (USA) 85(8), 1988, 2444-2448.
- the % identity values may also be calculated from BLAST alignments, algorithm blastp (protein-protein BLAST) or by applying the Clustal setting as given below.
- a percentage identity of a homologous polypeptide according to the invention means in particular the percentage identity of the amino acid residues relative to the total length of one of the amino acid sequences concretely described herein.
- “functional equivalents” according to the invention comprise proteins of the type designated above in deglycosylated or glycosylated form as well as modified forms that can be obtained by altering the glycosylation pattern.
- Such functional equivalents or homologues of the proteins or polypeptides according to the invention can be produced by mutagenesis, e.g. by point mutation, lengthening or shortening of the protein.
- Such functional equivalents or homologues of the proteins according to the invention can be identified by screening combinatorial databases of mutants, for example shortening mutants.
- a variegated database of protein variants can be produced by combinatorial mutagenesis at the nucleic acid level, e.g. by enzymatic ligation of a mixture of synthetic oligonucleotides.
- Chemical synthesis of a degenerated gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic gene can then be ligated in a suitable expression vector.
- the use of a degenerated genome makes it possible to supply all sequences in a mixture, which code for the desired set of potential protein sequences.
- Methods of synthesis of degenerated oligonucleotides are known to a person skilled in the art (e.g. Narang, S.A. (1983) Tetrahedron 39:3; ltakura et al. (1984) Annu. Rev. Biochem. 53:323; ltakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acids Res.
- REM Recursive Ensemble Mutagenesis
- the invention also relates to nucleic acid sequences that code for enzymes/proteins as defined herein.
- the present invention also relates to nucleic acids with a certain degree of "identity" to the sequences specifically disclosed herein.
- Identity between two nucleic acids means identity of the nucleotides, in each case over the entire length of the nucleic acid. For example the identity may be calculated by means of the Vector NTI Suite 7.1 program of the company Informax (USA) employing the Clustal Method (Higgins DG, Sharp PM. Fast and sensitive multiple sequence alignments on a microcomputer. Comput Appl. Biosci. 1989 Apr; 5(2):151-1 ) with the following settings:
- the identity may be determined according to Chenna, Ramu, Sugawara, Hideaki, Koike, Tadashi, Lopez, Rodrigo, Gibson, Toby J, Higgins, Desmond G, Thompson, Julie D. Multiple sequence alignment with the Clustal series of programs. (2003) Nucleic Acids Res 31 (13):3497-500 , th e we b pa g e : . httpi//wwjyv ⁇ and the following settings
- nucleic acid sequences mentioned herein can be produced in a known way by chemical synthesis from the nucleotide building blocks, e.g. by fragment condensation of individual overlapping, complementary nucleic acid building blocks of the double helix.
- Chemical synthesis of oligonucleotides can, for example, be performed in a known way, by the phosphoamidite method (Voet, Voet, 2nd edition, Wi l ey P ress , N ew York , pages 896-897).
- the accumulation of synthetic oligonucleotides and filling of gaps by means of the Klenow fragment of DNA polymerase and ligation reactions as well as general cloning techniques are described in Sambrook et al. (1989), see below.
- the invention also relates to nucleic acid sequences (single-stranded and double-stranded DNA and RNA sequences, e.g. cDNA and mRNA), coding for one of the above polypeptides and their functional equivalents, which can be obtained for example using artificial nucleotide analogs.
- nucleic acid sequences single-stranded and double-stranded DNA and RNA sequences, e.g. cDNA and mRNA
- coding for one of the above polypeptides and their functional equivalents which can be obtained for example using artificial nucleotide analogs.
- the invention relates both to isolated nucleic acid molecules, which code for polypeptides or proteins according to the invention or biologically active segments thereof, and to nucleic acid fragments, which can be used for example as hybridization probes or primers for identifying or amplifying coding nucleic acids according to the invention.
- nucleic acid molecules according to the invention can in addition contain non-translated sequences from the 3' and/or 5' end of the coding genetic region.
- the invention further relates to the nucleic acid molecules that are complementary to the concretely described nucleotide sequences or a segment thereof.
- nucleotide sequences according to the invention make possible the production of probes and primers that can be used for the identification and/or cloning of homologous sequences in other cellular types and organisms.
- probes or primers generally comprise a nucleotide sequence region which hybridizes under "stringent" conditions (see below) on at least about 12, preferably at least about 25, for example about 40, 50 or 75 successive nucleotides of a sense strand of a nucleic acid sequence according to the invention or of a corresponding antisense strand.
- nucleic acid molecule is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid and can moreover be substantially free from other cellular material or culture medium, if it is being produced by recombinant techniques, or can be free from chemical precursors or other chemicals, if it is being synthesized chemically.
- a nucleic acid molecule according to the invention can be isolated by means of standard techniques of molecular biology and the sequence information supplied according to the invention.
- cDNA can be isolated from a suitable cDNA library, using one of the concretely disclosed complete sequences or a segment thereof as hybridization probe and standard hybridization techniques (as described for example in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
- a nucleic acid molecule comprising one of the disclosed sequences or a segment thereof, can be isolated by the polymerase chain reaction, using the oligonucleotide primers that were constructed on the basis of this sequence.
- the nucleic acid amplified in this way can be cloned in a suitable vector and can be characterized by DNA sequencing.
- the oligonucleotides according to the invention can also be produced by standard methods of synthesis, e.g. using an automatic DNA synthesizer.
- Nucleic acid sequences according to the invention or derivatives thereof, homologues or parts of these sequences can for example be isolated by usual hybridization techniques or the PCR technique from other bacteria, e.g. via genomic or cDNA libraries. These DNA sequences hybridize in standard conditions with the sequences according to the invention.
- Hybridize means the ability of a polynucleotide or oligonucleotide to bind to an almost complementary sequence in standard conditions, whereas nonspecific binding does not occur between non-complementary partners in these conditions.
- the sequences can be 90-100% complementary.
- the property of complementary sequences of being able to bind specifically to one another is utilized for example in Northern Blotting or Southern Blotting or in primer binding in PCR or RT-PCR. Short oligonucleotides of the conserved regions are used advantageously for hybridization. However, it is also possible to use longer fragments of the nucleic acids according to the invention or the complete sequences for the hybridization.
- the hybridization conditions for DNA:DNA hybrids are 0.1 x SSC and temperatures between about 20 0 C to 45°C, preferably between about 30 0 C to 45°C.
- the hybridization conditions are advantageously 0.1 x SSC and temperatures between about 30 0 C to 55°C, preferably between about 45°C to 55°C.
- Hybridization can in particular be carried out under stringent conditions. Such hybridization conditions are for example described in Sambrook, J., Fritsch, E. F., Maniatis, T., in: Molecular Cloning (A Laboratory Manual), 2nd edition, Cold Spring Harbor Laboratory Press, 1989, pages 9.31-9.57 or in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
- “Stringent” hybridization conditions mean in particular: Incubation at 42°C overnight in a solution consisting of 50% formamide, 5 x SSC (750 mM NaCI, 75 mM tri-sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt Solution, 10% dextran sulfate and 20 g/ml denatured, sheared salmon sperm DNA, followed by washing of the filters with 0.1 x SSC at 65°C.
- the invention also relates to derivatives of the concretely disclosed or derivable nucleic acid sequences.
- nucleic acid sequences according to the invention can be derived from the sequences specifically disclosed herein and can differ from it by addition, substitution, insertion or deletion of individual or several nucleotides, and furthermore code for polypeptides with the desired profile of properties.
- the invention also encompasses nucleic acid sequences that comprise so-called silent mutations or have been altered, in comparison with a concretely stated sequence, according to the codon usage of a special original or host organism, as well as naturally occurring variants, e.g. splicing variants or allelic variants, thereof.
- the invention also relates to the molecules derived from the concretely disclosed nucleic acids by sequence polymorphisms. These genetic polymorphisms can exist between individuals within a population owing to natural variation. These natural variations usually produce a variance of 1 to 5% in the nucleotide sequence of a gene.
- nucleic acid sequences according to the invention mean for example allelic variants, having at least 60% homology at the level of the derived amino acid, preferably at least 80% homology, quite especially preferably at least 90% homology over the entire sequence range (regarding homology at the amino acid level, reference should be made to the details given above for the polypeptides).
- the homologies can be higher over partial regions of the sequences.
- derivatives are also to be understood to be homologues of the nucleic acid sequences according to the invention, for example animal, plant, fungal or bacterial homologues , shortened sequences, single-stranded DNA or RNA of the coding and noncoding DNA sequence.
- homologues have, at the DNA level, a homology of at least 40%, preferably of at least 60%, especially preferably of at least 70%, quite especially preferably of at least 80% over the entire DNA region given in a sequence specifically disclosed herein.
- derivatives are to be understood to be, for example, fusions with promoters.
- the promoters that are added to the stated nucleotide sequences can be modified by at least one nucleotide exchange, at least one insertion, inversion and/or deletion, though without impairing the functionality or efficacy of the promoters. Moreover, the efficacy of the promoters can be increased by altering their sequence or can be exchanged completely with more effective promoters even of organisms of a different genus.
- a skilled reader may generate arbitrary or directed mutations in genes or non-coding nucleic acid regions (which, for example, may be of importance for regulating gene expression) and, afterwards, may generate suitable gene libraries.
- the molecular biological method required therefore all well known in the art, and, for example, described by Sambrook and Russell, Molecular Cloning. 3. Edition, Cold Spring Harbor Laboratory Press 2001.
- PCR - error-prone polymerase chain reaction
- nucleotide sequences are mutated via the action of an incorrectly functioning DNA-polymerase (Eckert KA, Kunkel TA (1990) Nucleic Acids Res 18:3739);
- Those genes expressing functional mutants showing the desired feature profile may be selected and subjected to further mutation.
- the steps of mutation and selection or screening may be repeated iteratively until one of the obtained mutants shows the desired feature profile.
- a limited number of mutations as for example 1 to 5 mutations, may be performed and their influence on the enzyme feature at issue may be evaluated and further improved mutants may be selected stepwise. Said selected mutant may then be subjected to a further mutation in substantially the same may.
- the number of single mutants to be evaluated may be reduced significantly in this way.
- the teaching of the present invention provide important information as regards structure and sequence of the enzyme/ protein at issue, based on which it should be possible to generate further enzymes/proteins with the desired modified feature profile. In particular, so-called hot spots, i.e. sequence regions may be defined, which potentially may be suited for further mutation in order to modify or generate a desired feature of the enzyme/protein.
- the invention also relates to expression constructs, containing, under the genetic control of regulatory nucleic acid sequences, a nucleic acid sequence coding for a polypeptide or fusion protein according to the invention; as well as vectors comprising at least one of these expression constructs.
- “Expression unit” means, according to the invention, a nucleic acid with expression activity, which comprises a promoter as defined herein and, after functional association with a nucleic acid that is to be expressed or a gene, regulates the expression, i.e. the transcription and the translation of this nucleic acid or of this gene. In this context, therefore, it is also called a “regulatory nucleic acid sequence”. In addition to the promoter, other regulatory elements may be present, e.g. enhancers.
- “Expression cassette” or “expression construct” means, according to the invention, an expression unit, which is functionally associated with the nucleic acid that is to be expressed or the gene that is to be expressed.
- an expression cassette thus comprises not only nucleic acid sequences which regulate transcription and translation, but also the nucleic acid sequences which should be expressed as protein as a result of the transcription and translation.
- expression or “overexpression” describe, in the context of the invention, the production or increase of intracellular activity of one or more enzymes in a microorganism, which are encoded by the corresponding DNA.
- constructs according to the invention comprise a promoter 5'- upstream from the respective coding sequence, and a terminator sequence 3'- downstream, and optionally further usual regulatory elements, in each case functionally associated with the coding sequence.
- a “promoter”, a “nucleic acid with promoter activity” or a “promoter sequence” mean, according to the invention, a nucleic acid which, functionally associated with a nucleic acid that is to be transcribed, regulates the transcription of this nucleic acid.
- “Functional” or “operative” association means, in this context, for example the sequential arrangement of one of the nucleic acids with promoter activity and of a nucleic acid sequence that is to be transcribed and optionally further regulatory elements, for example nucleic acid sequences that enable the transcription of nucleic acids, and for example a terminator, in such a way that each of the regulatory elements can fulfill its function in the transcription of the nucleic acid sequence.
- regulatory elements for example nucleic acid sequences that enable the transcription of nucleic acids, and for example a terminator, in such a way that each of the regulatory elements can fulfill its function in the transcription of the nucleic acid sequence.
- Genetic control sequences such as enhancer sequences, can also exert their function on the target sequence from more remote positions or even from other DNA molecules. Arrangements are preferred in which the nucleic acid sequence that is to be transcribed is positioned behind (i.e.
- the distance between the promoter sequence and the nucleic acid sequence that is to be expressed transgenically can be less than 200 bp (base pairs), or less than 100 bp or less than 50 bp.
- examples of other regulatory elements that may be mentioned are targeting sequences, enhancers, polyadenylation signals, selectable markers, amplification signals, replication origins and the like. Suitable regulatory sequences are described for example in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
- Nucleic acid constructs according to the invention comprise in particular sequences selected from those, specifically mentioned herein or derivatives and homologues thereof, as well as the nucleic acid sequences that can be derived from amino acid sequences specifically mentioned herein which are advantageously associated operatively or functionally with one or more regulating signal for controlling, e.g. increasing, gene expression.
- the natural regulation of these sequences can still be present in front of the actual structural genes and optionally can have been altered genetically, so that natural regulation is switched off and the expression of the genes has been increased.
- the nucleic acid construct can also be of a simpler design, i.e. without any additional regulatory signals being inserted in front of the coding sequence and without removing the natural promoter with its regulation. Instead, the natural regulatory sequence is silenced so that regulation no longer takes place and gene expression is increased.
- a preferred nucleic acid construct advantageously also contains one or more of the aforementioned enhancer sequences, functionally associated with the promoter, which permit increased expression of the nucleic acid sequence. Additional advantageous sequences, such as other regulatory elements or terminators, can also be inserted at the 3' end of the DNA sequences.
- One or more copies of the nucleic acids according to the invention can be contained in the construct.
- the construct can also contain other markers, such as antibiotic resistances or auxotrophy- complementing genes, optionally for selection on the construct.
- promoters such as cos-, tac-, trp-, tet-, trp-tet-, Ipp-, lac-, Ipp-lac-, lacl q" ' T7-, T5-, T3-, gal-, trc-, ara-, rhaP (rhaP BAD )SP6-, Iambda-P R - or in the Iambda-P L promoter, which find application advantageously in Gram-negative bacteria.
- nucleic acid construct is inserted in a host organism advantageously in a vector, for example a plasmid or a phage, which permits optimum expression of the genes in the host.
- vectors are also to be understood as meaning all other vectors known to a person skilled in the art, e.g.
- viruses such as SV40, CMV, baculovirus and adenovirus, transposons, IS elements, phasmids, cosmids, and linear or circular DNA. These vectors can be replicated autonomously in the host organism or can be replicated chromosomally. These vectors represent a further embodiment of the invention.
- Suitable plasmids are, for example in E. coli, pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHS1 , pKK223-3, pDHE19.2, pHS2, pPLc236, pMBL24, pLG200, pUR290, plN-IN 113 -B 1 , ⁇ gt1 1 or p Bd C I ; i n nocard ioform actinomycetes pJAM2; in Streptomyces plJ101 , plJ364, plJ702 or plJ361 ; in bacillus pUB110, pC194 or pBD214; in Corynebacterium pSA77 or pAJ667; in fungi pALS1 , plL2 or pBB1 16; in yeasts 2alphaM, pAG-1 , YEp6, YE
- the aforementioned plasmids represent a small selection of the possible plasmids.
- Other plasmids are well known to a person skilled in the art and will be found for example in the book Cloning Vectors (Eds. Pouwels P. H. et al. Elsevier, Amsterdam-New York-Oxford, 1985, ISBN 0 444 904018). Further suitable plasmid are also mentioned in the experimental part.
- the vector containing the nucleic acid construct according to the invention or the nucleic acid according to the invention can be inserted advantageously in the form of a linear DNA in the microorganisms and integrated into the genome of the host organism through heterologous or homologous recombination.
- This linear DNA can comprise a linearized vector such as plasmid or just the nucleic acid construct or the nucleic acid according to the invention.
- codon usage can easily be determined on the basis of computer evaluations of other, known genes of the organism in question.
- an expression cassette according to the invention is based on fusion of a suitable promoter with a suitable coding nucleotide sequence and a terminator signal or polyadenylation signal.
- Common recombination and cloning techniques are used for this, as described for example in T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989) as well as in TJ. Silhavy, M. L. Berman and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and in Ausubel, F. M. et al., Current Protocols in Molecular Biology, Greene Publishing Assoc, and Wiley lnterscience (1987).
- the recombinant nucleic acid construct or gene construct is inserted advantageously in a host-specific vector for expression in a suitable host organism, to permit optimum expression of the genes in the host.
- Vectors are well known to a person skilled in the art and will be found for example in "Cloning Vectors" (Pouwels P. H. et al., Publ. Elsevier, Amsterdam-New York-Oxford, 1985).
- microorganism means the starting microorganism (wild-type) or a genetically modified microorganism according to the invention, or both.
- wild-type means, according to the invention, the corresponding starting microorganism, and need not necessarily correspond to a naturally occurring organism.
- recombinant microorganisms can be produced, which have been transformed for example with at least one vector according to the invention and can be used for the fermentative production according to the invention.
- the recombinant constructs according to the invention are inserted in a suitable host system and expressed.
- a suitable host system Preferably, common cloning and transfection methods that are familiar to a person skilled in the art are used, for example co-precipitation, protoplast fusion, electroporation, retroviral transfection and the like, in order to secure expression of the stated nucleic acids in the respective expression system.
- Suitable systems are described for example in Current Protocols in Molecular Biology, F. Ausubel et al., Publ. Wiley Interscience, New York 1997, or Sambrook et al. Molecular Cloning: A Laboratory Manual. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
- the parent microorganisms are typically those which have the ability to produce glutaconate, in particular (E)-glutaconate, from glucose and or glutamate.
- bacteria are bacteria, in particular of the orders Clostridials and Fusobacteriales.
- the species A. fermentans (DSM 20731 ), C. symbiosium (DSM 934), C. sporospaeroides (DSM 1294), P. assacharolyticus (ATCC 14963) and F. nucleatum subsp. nucleatum (DSM 15643) have to be mentioned.
- ATCC designates American type strain culture collection, and DSM designates
- the host organism or host organisms according to the invention preferably contain at least one of the nucleic acid sequences, nucleic acid constructs or vectors described in this invention, which code for an enzyme activity according to the above definition.
- the invention relates to methods for the fermentative production of glutaconate and related compounds of formula (I).
- the recombinant microorganisms as used according to the invention can be cultivated continuously or discontinuously in the batch process or in the fed batch or repeated fed batch process.
- a review of known methods of cultivation will be found in the textbook by Chmiel (Bioreatechnik 1. Einf ⁇ hrung in die Biovonstechnik (Gustav Fischer Verlag, Stuttgart, 1991 )) or in the textbook by Storhas (Bioreaktoren und periphere bamboo (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).
- the culture medium that is to be used must satisfy the requirements of the particular strains in an appropriate manner. Descriptions of culture media for various microorganisms are given in the handbook "Manual of Methods for General Bacteriology” of the American Society for Bacteriology (Washington D. C, USA, 1981 ). These media that can be used according to the invention generally comprise one or more sources of carbon, sources of nitrogen, inorganic salts, vitamins and/or trace elements.
- Preferred sources of carbon are sugars, such as mono-, di- or polysaccharides. Very good sources of carbon are for example glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose.
- Sugars can also be added to the media via complex compounds, such as molasses, or other by-products from sugar refining. It may also be advantageous to add mixtures of various sources of carbon.
- Other possible sources of carbon are oils and fats such as soybean oil, sunflower oil, peanut oil and coconut oil, fatty acids such as palmitic acid, stearic acid or linoleic acid, alcohols such as glycerol, methanol or ethanol and organic acids such as acetic acid or lactic acid.
- Sources of nitrogen are usually organic or inorganic nitrogen compounds or materials containing these compounds.
- sources of nitrogen include ammonia gas or ammonium salts, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea, amino acids or complex sources of nitrogen, such as corn-steep liquor, soybean flour, soybean protein, yeast extract, meat extract and others.
- the sources of nitrogen can be used separately or as a mixture.
- Inorganic salt compounds that may be present in the media comprise the chloride, phosphate or sulfate salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.
- Inorganic sulfur-containing compounds for example sulfates, sulfites, dithionites, tetrathionates, thiosulfates, sulfides, but also organic sulfur compounds, such as mercaptans and thiols, can be used as sources of sulfur.
- Phosphoric acid, potassium dihydrogenphosphate or dipotassium hydrogenphosphate or the corresponding sodium-containing salts can be used as sources of phosphorus.
- Chelating agents can be added to the medium, in order to keep the metal ions in solution.
- suitable chelating agents comprise dihydroxyphenols, such as catechol or protocatechuate, or organic acids, such as citric acid.
- the fermentation media used according to the invention may also contain other growth factors, such as vitamins or growth promoters, which include for example biotin, riboflavin, thiamine, folic acid, nicotinic acid, pantothenate and pyridoxine.
- growth factors and salts often come from complex components of the media, such as yeast extract, molasses, corn-steep liquor and the like.
- suitable precursors can be added to the culture medium.
- the precise composition of the compounds in the medium is strongly dependent on the particular experiment and must be decided individually for each specific case. Information on media optimization can be found in the textbook "Applied Microbiol. Physiology, A Practical Approach" (Publ. P.M. Rhodes, P. F.
- Growing media can also be obtained from commercial suppliers, such as Standard 1 (Merck) or BHI (Brain heart infusion, DIFCO) etc. All components of the medium are sterilized, either by heating (20 min at 2.0 bar and 121 0 C) or by sterile filtration. The components can be sterilized either together, or if necessary separately. All the components of the medium can be present at the start of growing, or optionally can be added continuously or by batch feed.
- the temperature of the culture is normally between 15°C and 45°C, preferably 25°C to 40 0 C and can be kept constant or can be varied during the experiment.
- the pH value of the medium should be in the range from 5 to 8.5, preferably around 7.0.
- the pH value for growing can be controlled during growing by adding basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water or acid compounds such as phosphoric acid or sulfuric acid.
- Antifoaming agents e.g. fatty acid polyglycol esters, can be used for controlling foaming.
- suitable substances with selective action e.g. antibiotics, can be added to the medium.
- Oxygen or oxygen-containing gas mixtures e.g. the ambient air, are fed into the culture in order to maintain aerobic conditions.
- the temperature of the culture is normally from 20 0 C to 45°C. Culture is continued until a maximum of the desired product has formed. This is normally achieved within 10 hours to 160 hours.
- the cells can be disrupted optionally by high-frequency ultrasound, by high pressure, e.g. in a French pressure cell, by osmolysis, by the action of detergents, lytic enzymes or organic solvents, by means of homogenizers or by a combination of several of the methods listed.
- the methodology of the present invention can further include a step of recovering glutaconate or related compounds.
- the term "recovering” includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (e.g., anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (e.g., with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), distillation, dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like.
- a conventional resin e.g., anion or cation exchange resin, non-ionic ad
- glutaconate can be recovered from culture media by first removing the microorganisms. The remaining broth is then passed through or over a cation exchange resin to remove unwanted cations and then through or over an anion exchange resin to remove unwanted inorganic anions and organic acids.
- the present invention provides a process for the production of polyesters or polyamides (e.g. nylon ® or related polymers) comprising a step as mentioned above for the production of glutaconate compounds.
- the glutaconate compound is reacted in a known manner with di-, tri- or polyamines to get polyamides or with di-, tri- or polyols to obtain polyesters.
- the glutaconate-type compound is reacted with polyamine or polyol containing 4 to 10 carbons.
- the present invention provides method of preparing a polymer, in particular copolymers, which method comprises preparing a mono-unsaturated dicarboxylic acid compounds of the general formula (I) as defined above a by method as described therein, isolating said compound; and polymerizing said compound with at least one suitable unsaturated polymerizable monomer, preferably in the presence of a polymerization initiator, like for example sodiumperoxide disulfate (NAPS) as radical initiator.
- a polymerization initiator like for example sodiumperoxide disulfate (NAPS) as radical initiator.
- sutable co-monomers for performing the above polymerization reactions there may be mentioned:
- polyols such as ethylene glycol, propylene glycol, glycerol, polyglycerols having 2 to 8 glycerol units, erythritol, pentaerythritol, and sorbitol.
- polyamines such as diamines, triamines and tetraamines, like ethylene diamine, propylene diamine, butylene diamine, neopentyl diamine, hexamethylene diamine, octamethylene diamine, diethylene triamine, triethylene tetramine, tetraethylene pentamine, dipropylene triamine, tripropylene tetramine, dihexamethylene triamine, aminopropylethylenediamine and bisaminopropylethylenediamine.
- Suitable polyamines are also polyalkylenepolyamines. The higher polyamines can be present in a mixture with diamines.
- Useful diamines include for example 1 ,2-diaminoethane, 1 ,3- diaminopropane, 1 ,4-diaminobutane, 1 ,5-diaminopentane, 1 ,6-diaminohexane, 1 ,8- diaminooctane.
- alkenes in particular C 2 -Ci 2 -alkenes which are monounsaturated linear or branched hydrocarbons having from 2 to 12 carbon atoms, as for example ethylene, 1- or 2-propylene, 1-, 2- and 3-butylene, 2-methyl-propylen, 1-, 2-, 3- and 4-pentenylene, 1-, 2-, 3-, 4- and 5-hexylene, 1-, 2-, 3-, 4-, 5- and 6-heptylene, or 1-, 2-, 3-, 4-, 5-, 6- and 7-octylene, 1-decene, 1-dodecene;and also their constitutional isomers.
- C 2 -Ci 2 -alkenes which are monounsaturated linear or branched hydrocarbons having from 2 to 12 carbon atoms, as for example ethylene, 1- or 2-propylene, 1-, 2- and 3-butylene, 2-methyl-propylen, 1-, 2-, 3- and 4-pentenylene, 1-, 2-, 3-, 4- and 5-hexylene
- mono-unsaturated C 3 -C 8 -carboxylic acids like acrylic acid or (d-C 7 -alkyl) acrylic acids, vinylacetic acid, crotonic acid, fumaric acid, maleic acid, itaconic acid esters of monoethylenically unsaturated C 3 -C 8 monocarboxylic acids with C 1 -C 2 0 alkanols, C 5 -C 8 cycloalkanol, phenyl-Ci-C 4 alkanols or phenoxy-Ci-C 4 alkanols, examples being esters of acrylic acid with C 1 -C 2 0 alkanols, such as methyl acrylate, ethyl acrylate, n-butyl acrylate, 2-butyl acrylate, isobutyl acrylate, tert-butyl acrylate, 2- ethylhexyl acrylate, decyl acrylate, lauryl acrylate and
- C1-C20 alkylamides and di-Ci-C 2 o alkylamides of monoethylenically unsaturated C 3 -C 8 monocarboxylic acids especially the C1-C20 alkylamides and di-Ci-C 2 o alkylamides of acrylic acid and of methacrylic acid, for example, amides of monoethylenically unsaturated carboxylic acids, such as acrylamide or methacrylamide,
- anhydrides of monoethylenically unsaturated monocarboxylic and dicarboxylic acids having 3 to 8 C atoms such as acrylic acid anhydride, methacrylic acid anhydride, maleic anhydride or itaconic anhydride,
- hydroxyl-C 2 -C 4 alkyl esters of monoethylenically unsaturated monocarboxylic or dicarboxylic acids having 3 to 8 C atoms such as 2-hydroxyethyl acrylate, 2-hydroxypropyl acrylate, 3-hydroxypropyl acrylate, 2-hydroxybutyl acrylate, 4-hydroxybutyl acrylate, 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, 3-hydroxypropyl methacryl a t e , 2-hydroxybutyl methacrylate, 4-hydroxybutyl methacrylate,
- monoethylenically unsaturated sulfonic acids and their salts examples being vinylsulfonic acid, allylsulfonic acid, methallylsulfonic acid, styrenesulfonic acid, 2- acrylamido-2-methylpropanesulfonic acid, 2-methacrylamido-2-methylpropanesulfonic acid, 2-acrylamidoethanesulfonic acid, 2-methacrylamidoethanesulfonic acid, 2-acryloyloxyethanesulfonic acid, 2-methacryloyloxyethanesulfonic acid, 3-acryloyloxypropanesulfonic acid and 2-methacryloyloxypropanesulfonic acid,
- monoethylenically unsaturated nitriles having 3 to 5 C atoms such as acrylonitrile and methacrylonitrile
- N-vinyl heterocycles such as N-vinylpyrrolidone, N-vinylcaprolactam, N- vinylimidazole, and
- monoethylenically unsaturated compounds having at least one PoIy-C 2 -C 4 alkylene oxide group, examples being vinyl ethers and allyl ethers of poly-C 2 -C 4 alkylene glycols or C 1 -C 1 0 alkyl-poly-C 2 -C 4 alkylene glycols, esters of monoethylenically unsaturated monocarboxylic and dicarboxylic acids having 3 to 8 C atoms with poly-C 2 - C 4 alkylene glycols or C1-C10 alkyl-poly-C 2 -C 4 alkylene glycols, amides of monoethylenically unsaturated monocarboxylic and dicarboxylic acids having 3 to 8 C atoms with poly-C 2 -C 4 alkylene glycol amines or C 1 -C 1 0 alkyl-poly-C 2 -C 4 alkylene glycol amines
- ethylenically unsaturated compounds having at least one having a basic nitrogen or quaternized nitrogen atom such as diallyldimethyl ammonium chloride, N-methyl-N- vinylimidazolium salts such as the chloride, sulfate or methosulfate, N-(2- (dimethylamino)ethyl) acrylamide, 2-(N,N-dimethylamino)ethyl acrylate,
- vinyl aromatic monomers such as styrene, ⁇ -methylstyrene, vinyltoluene, tert- butylstyrene, vinylpyridines;
- vinyl and allyl esters of aliphatic carboxylic acids having 1 to 20 C atoms examples being vinyl acetate, vinyl propionate, vinyl butyrate, vinyl hexanoate, vinyl laurate, and vinyl stearate;
- conjugated diolefins such as butadiene and isoprene
- halovinyl compounds such as chloroethene (vinyl chloride), 1 ,1-dichloroethene (vinylidene chloride), fluoroethene, 1 ,1-difluoroethene, and tetrafluoroethene.
- akyl mar refer to Ci-C 7 -alkyl and may be methyl, ethyl, propyl, isopropyl, n-butyl, 2-butyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1 ,2-dimethylpropyl, 1 ,1-dimethylpropyl, 2,2-dimethyl- propyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,3-dimethylbutyl, 1 ,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-di methylbutyl , 1 , 1 ,2-trimethylpropyl, 1 ,2,
- E. coli DH 5 Ci used for cloning
- E. coli BL21 used for expression were grown under anaerobic conditions at room temperature on Standard I medium (1.5% peptone, 0.3% yeast extract, 100 mM NaCI, 5 mM glucose; Merck, Darmstadt), supplemented with 50 mM MOPS, 3 mM cysteine hydrochloride, 10 mM Na-glutamate, riboflavin and FeCI 2 , at various concentrations.
- Reagents used in assay are 0.1 M potassium phosphate pH 7.0, 0.2 M sodium acetate, 1 m M oxaloacetate, 1 m M 5,5'-dithiobis(2-nitrobenzoate) (DTNB), 20 ⁇ g citrate synthase, 0.1 mM glutaryl-CoA, total volume 0.5 ml (Buckel W, Dorn U, Semmler R (1981 ) Glutaconate CoA-transferase from Acidaminococcus fermentans.
- 2-Hydroxyglutaryl-CoA dehydratase activity was measured under anoxic conditions at ambient temperature in cuvettes of 0.5 ml total volume containing 50 mM Mops/KOH pH 7.0, 10 mM dithiothreitol, 5 mM MgCI 2 , 0.1 mM dithionite, 0.4 mM ATP, and 2-hydroxyglutarate dehydrogenase with activator. After 10 minutes of incubation the reaction was started with 2 mM acetyl-CoA and 2 mM (R)-2-hydroxyglutarate.
- Glutaconate was enzymatically determined with 2 mM acetyl-CoA, 50 mM potassium phosphate pH7.0, 0.25 mM NADPH, glutaconate and using a catalytic amount of enzymes glutaconate-CoA transferase, glutaconyl-CoA decarboxylase [3,5,6] and crotonyl-CoA carboxylase/reductase [9].
- the formation of NADP + was measured spectrophotometrically at 340 nm.
- Glutaconate was also determined by HPLC at room temperature with UV detection at 210 nm using a C18 reverse-phase column in 20 mM sulfuric acid.
- hgdAB (2-hydroxyglutaryl-CoA dehydratase) from C. symbiosum and its activator hgdC from A. fermentans
- pASK-IBA3plus vector IBA GmbH, Gottingen, Germany
- the ligation reaction (Table 2) was performed at 23°C. After one hour T4 DNA ligase (Fermentas) was inactivated by incubation at 65°C for 10 minutes. The salts from the ligation mixture were removed by drop dialysis, using a 0.025 ⁇ m Millipore membrane, at ambient temperature for 30 minutes. Ligation mixture was added to 50 ⁇ l competent E.coli DH 5 ⁇ cells and transferred to an Electroporation Cuvette (Molecular BioProducts). A pulse was given to the cuvette using the following settings: 25 ⁇ F, 1.8 kV and 200 Ohm. The cuvette was washed with 300 ⁇ l Standard I medium and transferred to a sterile 1 .5 ml Eppendorf tube.
- the transformation mixture was incubated for 1 h at 37°C and plated on a LB agar plate containing chloramphenicol (50 ⁇ g-ml "1 ). The agar plate was incubated overnight at 37°C. Ten white colonies were picked and separately incubated in Standard medium overnight at 37°C: DNA was extracted using the Fermentas kit and digested with BamHI and EcoNI. One out of three correct fragments was extracted from the gel and ligated with gctAB.
- gctAB genes were treated with two restriction enzymes Ndel and Xhol, which recognition sites were introduced by PCR reaction (Tables 3 and 4). Also the pACYCDuet-1 vector containing the hgdH gene, pACYCDuet-1_hgdH, was treated with the same restriction enzymes (Table 5). The ligation reaction and transformation were performed under conditions, explained in Table 6. Table 3. PCR reaction mixture
- the activator hgdC was introduced in pASK-IBA 3 vector, containing hgdAB genes. Both DNA were separately treated with restriction enzymes Eco47lll and MIsI (Fermentas) for 1 h at 37° C (Table 7). After digestion the enzyme was inactivated by incubation at 65°C for 20 minutes. The salts were removed by drop dialysis as above, at ambient temperature for 30 minutes. To the salt-free reaction, containing pASK-IBA 3_hgdAB, was added 1 ⁇ l (1 u/ ⁇ l) of Shrimp Alkaline Phosphatase (Fermentas), 2 ⁇ l of 10x Reaction buffer and incubated for 1 h at 37°C. The reaction was stopped by heating at 65°C for 15 minutes. Ligation reaction (Table 8) and transformation were performed under the conditions explained above. Carbenicillin (100 ⁇ g-ml "1 ) replaced chloramphenicol as antibiotic.
- the first step was the construction of a plasmid, which comprises the six genes of 2-hydroxyglutarate dehydrogenase (hgdH), glutaconate CoA-transferase (gctAB), and the activator of 2-hydroxyglutaryl-CoA dehydratase ⁇ hgdC) from A. fermentans as well as 2-hydroxyglutaryl-CoA dehydratase (hgdAB) from C. symbiosum (see example 1 ). Determination of enzyme activities
- glutaconate concentration in the medium was 0.30 ⁇ 0.05 mM; when glutamate was omitted, the concentration decreased to 0.1 mM (Table 10).
- glutaconate indeed was produced indicating that the enzymes work also in vivo.
- the precursor of glutaconate is glutamate, either added as such or from peptone, rather than glucose as initially anticipated.
- the cell-free extract was prepared from 590 mg wet packed cells (approx. 118 mg dried cells) in 20 ml 50 mM MOPS pH 7.4. Assuming a volume of 2.5 ml/g dried cells (Brock M, Bucket W (2004) On the mechanism of action of the antifungal agent propionate. Eur J Biochem 271:3227-41) the internal concentration of glutaconate rises from 0.23 mM to 16 mM.
- the original strain E. coli BL21 was grown and analysed under the same conditions as the recombinant strain and glutaconate was not detected.
- the substrate is most likely glutamate rather than glucose, because glutamate enhanced the production glutaconate threefold.
- glutamate present in the peptone most likely is the precursor of glutaconate (Table 10).
- the use of glucose as precursor requires an electron acceptor, which cannot be oxygen because of the extreme sensitivity of the activator towards this agent (Buckel W, Golding BT (2006) Radical enzymes in anaerobes. Annu Rev Microbiol 60:27-49; , Kim J, Darley DJ, Buckel W, Pierik AJ (2008) An allylic ketyl radical intermediate in clostridial amino-acid fermentation.
- the iron requirement stems from the iron sulfur clusters in the dehydratase (HgdAB) and its activator (HgdC).
- HgdAB dehydratase
- HgdC activator
- the slight improvement with riboflavin is probably due to riboflavin-5'-phosphate (FMN) as prosthetic group of the dehydratase (Hans M, Buckel W, Bill E (2000)
- Th e d ata further indicate that the concentration of glutaconate inside the cells (16 mM) is about 12-times higher than outside (1.4 mM).
- Example 3 Evaluation of alternative substrates for the enzymes of the glutaconate production pathway
- Non-limiting examples of further substrates are given below: a) 2-Hydroxyglutaryl-CoA dehydratase from Clostridium symbiosum and activator from Acidaminococcus fermentans
- This enzyme acts on (E)-glutaconate, glutarate, (R)-2-hydroxyglutarate, adipate; acetate, propionate, acrylate (Buckel, W., Dorn, U. & Semmler, R. 1981. Glutaconate CoA-transferase from Acidaminococcus fermentans. Eur. J. Biochem. 118, 315-321 ).
- (R)-2-Hydroxyglutaryl-CoA, (E)-glutaconyl-CoA, muconyl-CoA, butynedioyl-CoA (acetylenedicarboxyl-CoA), 4-oxo-hex-2-eneoyl-CoA, 4-nitro-but-2-enoyl-CoA and (RS)-2-hydroxyadipoyl-CoA were prepared by this enzyme using acetyl-CoA and an excess of the neutralised acid. Since the R-emantiomers react faster than S, the product should be mainly (R)-2-hydroxyadipoyl-CoA (Anutthaman Parthasarathy and Wolfgang Buckel, unpublished).
- glycosyl (glutaconic acid:acrylic acid) were synthesized via radical polymerization methods in water solution using sodium peroxide disulfate (NAPS) as radical initiator.
- NAPS sodium peroxide disulfate
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The present invention relates to a novel method for the biocatalytic production of unsaturated dicarboxylic acids by cultivating a recombinant microorganism co-expressing a glutaconate CoA-transferase and a 2-hydroxyglutaryl-CoA dehydratase system. The present invention also relates to corresponding recombinant hosts, recombinant vectors, expression cassettes and nucleic acids suitable for preparing such hosts as well as a method of preparing polyamide or polyester copolymers making use of said dicarboxylic acids as obtained by said biocatalytic production method.
Description
Method for the production of glutaconate
The present invention relates to a novel method for the biocatalytic production of unsaturated dicarboxylic acids by cultivating a recombinant microorganism co-expressing a glutaconate CoA-transferase and a 2-hydroxyglutaryl-CoA dehydratase system. The present invention also relates to corresponding recombinant hosts, recombinant vectors, expression cassettes and nucleic acids suitable for preparing such hosts as well as a method of preparing polymers, as for example polyamide or polyester copolymers, making use of said dicarboxylic acids as obtained by said biocatalytic production method.
Background of the invention
Glutaconic acid is an α,β-unsaturated C5-dicarboxylic acid (2-pentenedioic acid) that accumulates in individuals with glutaric acidemia type I (Hoffmann GF, Zschocke J (1999) Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy. J Inherit Metab Dis 22:381-391). Glutaconic acid together with a diamine can polymerize to a polyamide related to Nylon®. The ideal material for biotechnological production of glutaconic acid would be glutamic acid, which can be produced by sugar fermentation. The chemical deamination of α-amino acids to α,β- unsaturated acids is very difficult. On the contrary, the strictly anaerobic bacteria Acidaminococcus fermentans and Clostridium symbiosum can easily deaminate glutamate via α-ketoglutarate, (R)-2-hydroxyglutarate, (R)-2-hydroxyglutaryl-CoA, and glutaconyl-CoA to (£)-glutaconate (Buckel W (2001b) Unusual enzymes involved in five pathways of glutamate fermentation. Appl Microbiol Biotechnol 57:263-273). A. fermentans and C. symbiosum are not suitable for the production of glutaconic acid because they decarboxylate glutaconyl-CoA to crotonyl-CoA. Genetic manipulation of these organisms has not been established yet. Thus, the genes coding for glutaconyl- CoA decarboxylase cannot be attenuated to a low level, whereas a complete deletion would deprive these organisms of the ability to produce ATP. Furthermore, the ultimate aim is the production of glutaconate not from glutamate but from glucose, on which A. fermentans and C. symbiosum are not able to grow.
The object of the present invention is therefore to provide a suitable method for the fermentative, biocatalytic production of glutaconic acid and related dicarboxylic acids or corresponding salts thereof.
Description of the figures:
Figure 1 depicts the pathway for glutaconate production. The enzymes of the final steps are numbered with 1 , 2 and 3. 1 : 2-hydroxyglutarate dehydrogenase; 2: glutaconate CoA-transferase; 3: 2-hydroxyglutaryl-CoA dehydratase. Figure 2 depicts schematically the construction of recombinant plasmid pACYCDuet-1 (Fig. 2A) in which the coding sequences for 2-hydroxyglutarate dehydrogenase (hgdH) and glutaconate CoA-transferase (gctAB), (subunits A and B) are inserted (Fig. 2B).
Figure 3 depicts schematically the construction of recombinant plasmids pASK- IBA3plus (Fig. 3A) in which the coding sequences for 2-hydroxyglutaryl-CoA dehydratase (subunits hdgA and hgdB) and its activator (hdgC) are inserted (Fig. 3B).
Summary of the invention
The above-mentioned problem was solved by the present invention teaching a biocatalytic method for the production of an unsaturated dicarboxylic acid compound , like glutaconate or a structurally similar glutaconate compound (of formula I) which method comprises converting a corresponding 2-hydroxy-substituted dicarboxylic acid in a recombinant microorganism co-expressing a glutaconate CoA-transferase and a 2- hydroxyglutaryl-CoA dehydratase system, so that said unsaturated dicarboxylic acid is formed
For example, in order to convert Escherichia coli to a glutaconate producer, the present inventors expressed six genes, encoding 2-hydroxyglutarate dehydrogenase (HgdA, 1 in Fig. 1 ), glutaconate CoA-transferase (GcdAB, 2), 2-hydroxyglutaryl-CoA dehydratase (HgdAB, 3) and its activator (HgdC, 3). The new pathway can divert at α- ketoglutarate derived from glucose via the Embden-Meyerhof pathway and the citrate cycle.
Detailed description of the invention
1. Preferred embodiments
In a first embodiment the present invention provides a biocatalytic method for the production of an unsaturated dicarboxylic acid compound of the general formula I
HOOC-CH=CH-X-COOH (I) in particular the E-form of such a compound; wherein X represents a linear or branched, optionally unsaturated, optionally substituted hydrocarbon group, preferably having 1 , 2, 3 or 4 carbon atoms;
which method comprises converting a 2-hydroxy-substituted dicarboxylic acid III compound
HOOC-C(OH)H-CH2-X-COOH (III)
wherein X is as defined above;
in a recombinant microorganism co-expressing a glutaconate CoA-transferase (E. C. 2.8.3.12) and a 2-hydroxyglutaryl-CoA dehydratase system, under conditions allowing formation of the desired product, and particularly or optionally in the presence of a coenzyme A (CoA) source, like acyl-CoA, like C2-C6-acyl-CoA, and in particular acetyl- coenzyme A, which CoA source may be of any origin, like endogenic to said micoroorganism,. i.e. produced by said microorganism, or exogenic, i.e. added to said microorganism or production medium, so that said compound of formula I is formed, and/or optionally in the presence of any other exogenic or endogenic factors required for or improving formation of a compound of formula I; and optionally isolating said compound of formula I in the form of a substantially pure stereoisomer, as for example the Z-form or in particular the E-form, or as a mixture of stereoisomers, each either in the form of its salts or as free acid. In compounds of formula I said group X preferably may be selected from (CH2)n, with n being an integer from 1 to 4, CH=CH, CH2-C(=O), or CH=C(OH). In particular X is selected from CH2, C2H4, CH=CH and CH=C(OH).
According to the present invention said 2-hydroxy-substituted dicarboxylic acid III is preferably formed by said recombinant microorganism in a 2-hydroxyglutarate
dehydrogenase (E. C. 1.1.1.-) catalyzed conversion of a 2-oxo-dicarboxylic acid compound of formula Il
HOOC-C(=O)-CH2-X-COOH (II)
wherein X is defined above. In particular, said 2-hydroxyglutarate dehydrogenase may be co-expressed by said recombinant microorganism as well.
In said method of the invention said oxo-dicarboxylic acid compound of formula Il is either added to or fermentatively produced by said recombinant microorganism. In particular, the method of the invention comprises the cultivation of at least one recombinant microorganism, which microorganism is derived from a parent microorganism having the ability to produce said 2-oxo-dicarboxylic acid compound of formula Il as intermediary product of a metabolic pathway, and additionally having the ability to express heterologously at least one of the above mentioned enzymes and proteins. For example, said microorganism is a glutamate and/or glucose metabolizing aerobic or anaerobic recombinant bacterium, and said compound of formula Il is 2- oxoglutarate formed by the biodegradation of glutamate (for example by the action of glutamate dehydrogenase) and/or glucose (for example via the Embden-Meyerhof pathway and the Krebs or citric acid cycle). If appropriate one or more, as for example 2, 3, 4 or 5, individual enzymes involved in said glutamate or glucose metabolism may be deregulated in order to further assist, or improve the formation of the intended product and/or to reduce or avoid the formation of undesired side products or secondary products (formed by the metabolization of the intended product) which otherwise would lessen or decrease the actual amount or concentration of the intended product as formed by the microrganism .
In particular, said glutamate and/or glucose metabolizing recombinant bacterium is selected from bacteria of the genus Escherichia, as for example E. coli, like the strain E. coli BL21-CodonPlus® (DE3)-RIL strain (Stratgene). The CodonPlus plasmid responsible for chloramphenicol resistance may also be removed. In a particular embodiment of the method of the invention said 2-hydroxyglutaryl-
CoA dehydratase system comprises a 2-hydroxyglutaryl-CoA dehydratase (E. C. 4.2.1.) and, if required for inducing and/or maintaining the intended dehydratase activity, optionally an activator protein for said enzyme. Said activator protein may be required for establishing dehydratase activity.
According to the present invention said enzymes and proteins (glutaconate CoA- transferase, 2-hydroxyglutaryl-CoA dehydratase, activator, 2-hydroxyglutarate dehydrogenase) are of prokaryotic or eukaryotic origin. In particular they may originate from different microbial genera or strains. For example it is not an absolute requirement that dehydratase and the activator for establishing dehydratase activity are derived from the same microbial genus or strain as long as the activator cooperates with (activates the) dehydratase enzyme as used for the bioconversion reaction.
In a particular embodiment, said enzymes and activator originate from the same or different anaerobic bacterium, which bacterium being able to convert glutamate into glutaconate. For example, said anaerobic bacterium is selected from bacteria of the genus Acidaminococcus, Clostridium, Fusobacterium or Peptostreptococcus, in particular Acidaminococcus fermentans, Clostridium symbiosum, Clostridium sporosphaeroides, Fusobacterium nucleatum including all subspecies, or Peptostreptococcus asaccharolyticus. In particular, said 2-hydroxyglutarate dehydrogenase (HgdH) comprises at least one amino acid sequence of SEQ I D NO: 1 6 (FN0487, annotated as D-lactate dehydrogenase - Fusobacterium nucleatum subsp. nucleatum ATCC 25586; GenelD: 991766) or SEQ ID NO:2 (1XDW_A {A. fermentans); or a sequence having at least 50% identity to at least one of said sequences, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity, and still retaining the intended enzyme activity (or function), i.e. being applicable as HgdH enzyme; for example said enzyme may be a homodimer, as for example the A. fermentans enzyme; for example the A. fermentans enzyme shows 61 % sequence identity to the enzyme from F. nucleatum. I n particular, said glutaconate CoA transferase (GctAB), which may be a heterooctamer (α4β4)
(a) comprises at least one alpha (A) and at least one beta (B) subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 4 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 6 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as GctAB enzyme; or
(b) comprises at least one alpha and at least one beta subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 22 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 24 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as GctAB enzyme; or
(c) comprises at least one alpha and at least one beta subunit, wherein said alpha subunit comprising an amino acid sequence accord ing to S EQ I D NO : 1 8 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 20 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as GctAB enzyme.
In particular, said 2-hydroxyglutaryl-CoA dehydratase, which may be a heterodimer (AB) or trimer (ABD) with one [4Fe-4S] cluster in each A and each B subunit, and (a) comprises at least one alpha (A) and at least one beta (B) subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 26 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 28 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as dehydratase enzyme; or
(b) comprises at least one alpha (A), at least one beta (B) subunit and at least one delta (D) subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 30 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 32 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said gamma
subunit comprising an amino acid sequence according to SEQ ID NO: 34 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as dehydratase enzyme; or (c) comprises at least one alpha and at least one beta subunit, wherein said alpha subunit comprising an amino acid sequence according to SEQ ID NO: 8 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and wherein said beta subunit comprising an amino acid sequence according to SEQ ID NO: 10 or a sequence having at least 50% identity thereto, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme activity, i.e. being applicable as dehydratase enzyme.
In particular, said the activator protein comprises at least one amino acid sequence of SEQ ID NO: 12, 36 or 38 or a sequence having at least 50% identity to at least one of said sequences as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended activity, i.e. being applicable as dehydratase activator; an may be a homodimer with one [4Fe-4S] cluster between the two subunits.
In a further particular embodiment, said 2-hydroxyglutaryl-CoA dehydratase is from C. symbiosum (S EQ I D NO : 8 and/or 10); while said 2-hydroxyglutarate dehydrogenase (SEQ ID NO:2); said glutaconate CoA transferase (SEQ ID NO:4 and/or 6) and said activator protein (SEQ ID NO:12) are from A. fermentans; or independently of each other being derived there form, and having a sequence of at least 50% identity to the parent sequence, as for example at least 60, 70, 80, 85, 90, 92, 95, 96, 97, 98 or 99 % sequence identity; and still retaining the intended enzyme or activator activity. Said proteins may be present in the form of the active quaternary structure or may be present in the form of active fragments or subunits thereof.
Moreover, said proteins and enzymes may each be encoded by a nucleic acid sequence, which is adapted to the codon usage of said microorganism having the ability to produce said 2-oxo-dicarboxylic acid of formula II.
In addition, said proteins and enzymes may be encoded by nucleic acid sequences contained in one single or more expression vectors in may be encoded as single or multiple copies.
Additionally, at least one of said co-expressed proteins is heterologous to said recombinant microorganism.
The present invention also relates to : an expression cassette, comprising a combination of at least two different nucleic acid sequences encoding an enzyme or protein as defined above
(i.e. the required set (or a subset of) of sequences encoding the required set (or a subset) of enzymes/proteins necessary for producing compounds of formula I via compounds of formula III), which sequences are operatively linked to at least one regulatory nucleic acid sequence; - a recombinant vector, comprising at least one of said expression cassettes; a recombinant prokaryotic or eukaryotic host, transformed with at least one such vector.
In particular such recombinant hosts have the ability to produce a 2-oxo- dicarboxylic acid compound of formula (II), which is converted to a compound of formula (I) upon expression of said expression products as encoded by said at least one vector. For example said host may be a recombinant strain of a bacterium of the genus Escherichia.
In another embodiment the present invention relates to a method of preparing a polyamide or polyester, which method comprises a) preparing a mono-unsaturated dicarboxylic acid compounds of the general formula (I) as defined above a by method as described herein; b) isolating said compound optionally followed by hydrogenation in order to remove the C=C-double bond; and c) polymerizing said compound as obtained according to step b), with at least one suitable polyvalent polymerizable amine monomer or polyvalent polymerizable hydroxyl compound.
In particular, said polyamine is a di-amine, a tri-amine or a mixture thereof and said polyvalent hydroxyl compound is a diol or triol or a mixture thereof. For example said polymerization reaction may be performed in the presence of a suitable catalyst, as for example acid or base catalyst.
In another embodiment the present invention relates to a method of preparing a polymer, which method comprises
a) preparing a mono-unsaturated dicarboxylic acid compounds of the general formula (I) as defined above a by method as defined above; b) isolating said compound; and c) polymerizing said compound as obtained according to step b), with at least one suitable unsaturated polymerizable monomer.
For example, said polymerization may be performed in the presence of a suitable radical initiator. Suitable comonomers are those which may be applied in a radical- initiated polymerization, as for example monomers containing at least one polymerizable C=C-bond, like vinyl, acryl and methacryl. In another embodiment of the method described herein at least one gene, as for example 1 , 2, 3 or 4 genes, of a biosynthetic pathway in said recombinant microorganism directly or indirectly affecting the formation and/or decomposition of at least one compound of formula (I), (II) or (III), may deregulated (up or down regulated) in order to further optimize the method of the invention.
2. Explanation of particular terms
Unless otherwise stated the expressions "glutaconate" and "glutaconic acid" or the expressions "glutaconate compound" and "glutaconic acid compound" or the expressions "unsaturated dicarboxylic acid" or "unsaturated dicarboxylate compound" are considered to be synonymous. The glutaconate or dicarboxylic acid compound (of formula I) as obtained according to the present invention may be in the form of the free acid, in the form of a partial or complete salt of said acid or in the form of mixtures of the acid and its salt.
A dicarboxylic acid "salt" comprises for example metal salts, as for example zinc glutaconate, mono- or di-alkalimetal salts of said acid, like mono-sodium di-sodium, mono-potassium and di-potassium salts as well as alkaline earth metal salts as for example the calcium or magnesium salts.
The term "biocatalytic method" refers to any method performed in the presence of catalytic activity of an enzyme as defined herein, i.e. in the presence of isolated pure or crude enzyme or entire microbial cells containing or expression such enzyme activity.
The term ,,stereospecific" means that one of several stereoisomers or enantiomers is formed by the enzyme in high enantiomeric excess or purity, of at least 90%ee, preferably at least 95 %ee, in particular at least 98 %ee, or at least 99 %ee. the ee% value is calculated according to the following formula
ee% = [XA-XB]/[ XA+XB]*100, wherein XA and XB refer to the molar fraction of enantiomer A or B, respectively. Examples of "stereoisomers" are E-and Z- isomers or R- and S enantiomers. "Deregulation" has to be understood in its broadest sense, and comprises an increase or decrease of complete switch off of an enzyme (target enzyme) activity by different means well known to those in the art. Suitable methods comprise for example an increase or decrease of the copy number of gene and /or enzyme molecules in an organism, or the modification of another feature of the enzyme affecting the its enzymatic activity, which then results in the desired effect on a metabolic pathway at issue, or any pathway or enzymatic reaction coupled thereto. Suitable genetic manipulation can also include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (e.g., by removing strong promoters, inducible promoters or multiple promoters), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particu lar gene such as a ribosome bind ing site or transcription terminator, decreasing the copy number of a particular gene, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules), or other methods to knock-out or block expression of the target protein.
A preferred way of an "amplification" is an "up"- mutation which increases the gene activity e.g. by gene amplification using strong expression signals and/or point mutations which enhance the enzymatic activity. A preferred way of an "attenuation" is a "down"- mutation which decreases the gene activity e.g. by gene deletion or disruption, using weak expression signals and/or point mutations which destroy or decrease the enzymatic activity.
The term "heterologous" or "exogenous" refers to sequences as described herein, which are introduced into or produced (transcribed or translated) by a genetically manipulated microorganism as defined herein and which microorganism prior to said manipulation did not contain or did not produce said sequence. In particular said microorganism prior to said manipulation may not contain or express said heterologous enzyme activity, or may contain or express an endogenous enzyme of comparable activity or specificity, which is encoded by a different coding sequence
or by an enzyme of different amino acid sequence, and said endogenous enzyme may convert the same substrate or substrates as said exogenous enzyme.
A "parent" microorganism of the present invention is any microorganism having the ability to produce a compound of formula (II) as intermediary product. An "intermediary product" is understood as a product, which is transiently or continuously formed during a chemical or biochemical process, in a not necessarily analytically directly detectable concentration. Said "intermediary product" may be removed from said biochemical process by a second, chemical or biochemical reaction.
A "recombinant host" may be any prokaryotic or eukaryotic cell, which contains either a cloning vector or expression vector. This term is also meant to include those prokaryotic or eukaryotic cells that have been genetically engineered to contain the cloned gene(s) in the chromosome or genome of the host cell. For examples of suitable hosts, see Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989). The term "recombinant microorganism" includes a microorganism (e.g., bacteria, yeast cell, fungal cell, etc.) which has been genetically altered, modified or engineered (e.g., genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (e.g., when the genetic modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism or "parent" microorganism which it was derived from.
As used herein, a "substantially pure" protein or enzyme means that the desired purified protein is essentially free from contaminating cellular components, as evidenced by a single band following polyacrylamide-sodium dodecyl sulfate gel electrophoresis (SDS-PAGE). The term "substantially pure" is further meant to describe a molecu le, wh ich is homogeneous by one or more pu rity or homogeneity characteristics used by those of skill in the art. For example, a substantially pure enzyme or protein will show constant and reproducible characteristics within standard experimental deviations for parameters such as the following: molecular mass, chromatographic migration, amino acid composition, amino acid sequence, blocked or unblocked N-terminus, H PLC elution profile, biological activity, and other such parameters. The term, however, is not meant to exclude artificial or synthetic mixtures of said enzyme or protein with other compounds. In addition, the term is not meant to exclude fusion proteins optionally isolated from a recombinant host.
3. Further embodiments of the invention 3.1 Proteins according to the invention
The present invention is not limited to the specifically mentioned enzymes/proteins, but also extends to functional equivalents thereof. "Functional equivalents" or "analogs" or "functional mutations" of the concretely disclosed enzymes are, within the scope of the present invention, various polypeptides thereof, which moreover possess the desired biological function or activity, e.g. enzyme activity.
For example, "functional equivalents" means enzymes, which, in a test used for enzymatic activity, display at least a 1 to 10%, or at least 20%, or at least 50%, or at least 75%, or at least 90% higher or lower activity of an enzyme, as defined herein.
"Functional equivalents", according to the invention, also means in particular mutants, which, in at least one sequence position of the amino acid sequences stated above, have an amino acid that is different from that concretely stated, but nevertheless possess one of the aforementioned biological activities. "Functional equivalents" thus comprise the mutants obtainable by one or more amino acid additions, substitutions, deletions and/or inversions, where the stated changes can occur in any sequence position, provided they lead to a mutant with the profile of properties according to the invention. Functional equivalence is in particular also provided if the reactivity patterns coincide qualitatively between the mutant and the unchanged polypeptide, i.e. if for example the same substrates are converted at a different rate. Examples of suitable amino acid substitutions are shown in the following table:
Original residue Examples of substitution
Ala Ser
Arg Lys
Asn GIn; His
Asp GIu
Cys Ser
GIn Asn
GIu Asp
GIy Pro
His Asn ; GIn
Ne Leu; VaI
Leu lie; VaI
Lys Arg ; GIn ; GIu
Met Leu ; Ne
Phe Met ; Leu ; Tyr
Ser Thr
Thr Ser
Trp Tyr
Tyr Trp ; Phe
VaI lie; Leu
"Functional equivalents" in the above sense are also "precursors" of the polypeptides described, as well as "functional derivatives" and "salts" of the polypeptides. "Precursors" are in that case natural or synthetic precursors of the polypeptides with or without the desired biological activity.
The expression "salts" means salts of carboxyl groups as well as salts of acid addition of amino groups of the protein molecules according to the invention. Salts of carboxyl groups can be produced in a known way and comprise inorganic salts, for example sodium, calcium, ammonium, iron and zinc salts, and salts with organic bases, for example amines, such as triethanolamine, arginine, lysine, piperidine and the like. Salts of acid addition, for example salts with inorganic acids, such as hydrochloric acid or sulfuric acid and salts with organic acids, such as acetic acid and oxalic acid, are also covered by the invention. "Functional derivatives" of polypeptides according to the invention can also be produced on functional amino acid side groups or at their N-terminal or C-terminal end using known techniques. Such derivatives comprise for example aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, obtainable by reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino
groups, produced by reaction with acyl groups; or O-acyl derivatives of free hydroxy groups, produced by reaction with acyl groups.
"Functional equivalents" naturally also comprise polypeptides that can be obtained from other organisms, as well as naturally occurring variants. For example, areas of homologous sequence regions can be established by sequence comparison, and equivalent enzymes can be determined on the basis of the concrete parameters of the invention.
"Functional equivalents" also comprise fragments, preferably individual domains or sequence motifs, of the polypeptides according to the invention, which for example display the desired biological function.
"Functional equivalents" are, moreover, fusion proteins, which have one of the polypeptide sequences stated above or functional equivalents derived there from and at least one further, functionally different, heterologous sequence in functional N- terminal or C-terminal association (i.e. without substantial mutual functional impairment of the fusion protein parts). Non-limiting examples of these heterologous sequences are e.g. signal peptides, histidine anchors or enzymes.
"Functional equivalents" that are also included according to the invention are homologues of the concretely disclosed proteins. These possess percent identity values as stated above. Said values refer to the identity with the concretely disclosed amino acid sequences, and may be calculated according to the algorithm of Pearson and Lipman, Proc. Natl. Acad, Sci. (USA) 85(8), 1988, 2444-2448.
The % identity values may also be calculated from BLAST alignments, algorithm blastp (protein-protein BLAST) or by applying the Clustal setting as given below.
A percentage identity of a homologous polypeptide according to the invention means in particular the percentage identity of the amino acid residues relative to the total length of one of the amino acid sequences concretely described herein.
In the case of a possible protein glycosylation, "functional equivalents" according to the invention comprise proteins of the type designated above in deglycosylated or glycosylated form as well as modified forms that can be obtained by altering the glycosylation pattern.
Such functional equivalents or homologues of the proteins or polypeptides according to the invention can be produced by mutagenesis, e.g. by point mutation, lengthening or shortening of the protein.
Such functional equivalents or homologues of the proteins according to the invention can be identified by screening combinatorial databases of mutants, for example shortening mutants. For example, a variegated database of protein variants can be produced by combinatorial mutagenesis at the nucleic acid level, e.g. by enzymatic ligation of a mixture of synthetic oligonucleotides. There are a great many methods that can be used for the production of databases of potential homologues from a degenerated oligonucleotide sequence. Chemical synthesis of a degenerated gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic gene can then be ligated in a suitable expression vector. The use of a degenerated genome makes it possible to supply all sequences in a mixture, which code for the desired set of potential protein sequences. Methods of synthesis of degenerated oligonucleotides are known to a person skilled in the art (e.g. Narang, S.A. (1983) Tetrahedron 39:3; ltakura et al. (1984) Annu. Rev. Biochem. 53:323; ltakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acids Res. 11 :477). In the prior art, several techniques are known for the screening of gene products of combinatorial databases, which were produced by point mutations or shortening, and for the screening of cDNA libraries for gene products with a selected property. These techniques can be adapted for the rapid screening of the gene banks that were produced by combinatorial mutagenesis of homologues according to the invention. The techniques most frequently used for the screening of large gene banks, which are based on a high-throughput analysis, comprise cloning of the gene bank in expression vectors that can be replicated, transformation of the suitable cells with the resultant vector database and expression of the combinatorial genes in conditions in which detection of the desired activity facilitates isolation of the vector that codes for the gene whose product was detected. Recursive Ensemble Mutagenesis (REM), a technique that increases the frequency of functional mutants in the databases, can be used in combination with the screening tests, in order to identify homologues (Arkin and Yourvan (1992) PNAS 89:781 1-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331 ).
3.2 Coding nucleic acid sequences
The invention also relates to nucleic acid sequences that code for enzymes/proteins as defined herein.
The present invention also relates to nucleic acids with a certain degree of "identity" to the sequences specifically disclosed herein. "Identity" between two nucleic acids means identity of the nucleotides, in each case over the entire length of the nucleic acid. For example the identity may be calculated by means of the Vector NTI Suite 7.1 program of the company Informax (USA) employing the Clustal Method (Higgins DG, Sharp PM. Fast and sensitive multiple sequence alignments on a microcomputer. Comput Appl. Biosci. 1989 Apr; 5(2):151-1 ) with the following settings:
Multiple alignment parameters:
Gap opening penalty 10
Gap extension penalty 10
Gap separation penalty range 8
Gap separation penalty off
% identity for alignment delay 40
Residue specific gaps off
Hydrophilic residue gap off
Transition weighing 0
Pairwise alignment parameter:
FAST algorithm on
K-tuplesize 1
Gap penalty 3
Window size 5
Number of best diagonals 5
Alternatively the identity may be determined according to Chenna, Ramu, Sugawara, Hideaki, Koike, Tadashi, Lopez, Rodrigo, Gibson, Toby J, Higgins, Desmond G, Thompson, Julie D. Multiple sequence alignment with the Clustal series of programs. (2003) Nucleic Acids Res 31 (13):3497-500 , th e we b pa g e : .httpi//wwjyv^ and the following settings
DNA Gap Open Penalty 15.0
DNA Gap Extension Penalty 6.66
DNA Matrix Identity
Protein Gap Open Penalty 10.0
Protein Gap Extension Penalty 0.2
Protein matrix Gonnet
Protein/DNA ENDGAP -1 Protein/DNA GAPDIST 4
All the nucleic acid sequences mentioned herein (single-stranded and double- stranded DNA and RNA sequences, for example cDNA and mRNA) can be produced in a known way by chemical synthesis from the nucleotide building blocks, e.g. by fragment condensation of individual overlapping, complementary nucleic acid building blocks of the double helix. Chemical synthesis of oligonucleotides can, for example, be performed in a known way, by the phosphoamidite method (Voet, Voet, 2nd edition, Wi l ey P ress , N ew York , pages 896-897). The accumulation of synthetic oligonucleotides and filling of gaps by means of the Klenow fragment of DNA polymerase and ligation reactions as well as general cloning techniques are described in Sambrook et al. (1989), see below.
The invention also relates to nucleic acid sequences (single-stranded and double-stranded DNA and RNA sequences, e.g. cDNA and mRNA), coding for one of the above polypeptides and their functional equivalents, which can be obtained for example using artificial nucleotide analogs.
The invention relates both to isolated nucleic acid molecules, which code for polypeptides or proteins according to the invention or biologically active segments thereof, and to nucleic acid fragments, which can be used for example as hybridization probes or primers for identifying or amplifying coding nucleic acids according to the invention.
The nucleic acid molecules according to the invention can in addition contain non-translated sequences from the 3' and/or 5' end of the coding genetic region.
The invention further relates to the nucleic acid molecules that are complementary to the concretely described nucleotide sequences or a segment thereof.
The nucleotide sequences according to the invention make possible the production of probes and primers that can be used for the identification and/or cloning of homologous sequences in other cellular types and organisms. Such probes or primers generally comprise a nucleotide sequence region which hybridizes under
"stringent" conditions (see below) on at least about 12, preferably at least about 25, for example about 40, 50 or 75 successive nucleotides of a sense strand of a nucleic acid sequence according to the invention or of a corresponding antisense strand.
An "isolated" nucleic acid molecule is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid and can moreover be substantially free from other cellular material or culture medium, if it is being produced by recombinant techniques, or can be free from chemical precursors or other chemicals, if it is being synthesized chemically.
A nucleic acid molecule according to the invention can be isolated by means of standard techniques of molecular biology and the sequence information supplied according to the invention. For example, cDNA can be isolated from a suitable cDNA library, using one of the concretely disclosed complete sequences or a segment thereof as hybridization probe and standard hybridization techniques (as described for example in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). In addition, a nucleic acid molecule comprising one of the disclosed sequences or a segment thereof, can be isolated by the polymerase chain reaction, using the oligonucleotide primers that were constructed on the basis of this sequence. The nucleic acid amplified in this way can be cloned in a suitable vector and can be characterized by DNA sequencing. The oligonucleotides according to the invention can also be produced by standard methods of synthesis, e.g. using an automatic DNA synthesizer.
Nucleic acid sequences according to the invention or derivatives thereof, homologues or parts of these sequences, can for example be isolated by usual hybridization techniques or the PCR technique from other bacteria, e.g. via genomic or cDNA libraries. These DNA sequences hybridize in standard conditions with the sequences according to the invention.
"Hybridize" means the ability of a polynucleotide or oligonucleotide to bind to an almost complementary sequence in standard conditions, whereas nonspecific binding does not occur between non-complementary partners in these conditions. For this, the sequences can be 90-100% complementary. The property of complementary sequences of being able to bind specifically to one another is utilized for example in Northern Blotting or Southern Blotting or in primer binding in PCR or RT-PCR.
Short oligonucleotides of the conserved regions are used advantageously for hybridization. However, it is also possible to use longer fragments of the nucleic acids according to the invention or the complete sequences for the hybridization. These standard conditions vary depending on the nucleic acid used (oligonucleotide, longer fragment or complete sequence) or depending on which type of nucleic acid - DNA or RNA - is used for hybridization. For example, the melting temperatures for DNA:DNA hybrids are approx. 1O0C lower than those of DNA:RNA hybrids of the same length.
For example, depending on the particular nucleic acid, standard conditions mean temperatures between 42 and 58°C in an aqueous buffer solution with a concentration between 0.1 to 5 x SSC (1 X SSC = 0.15 M NaCI, 15 mM sodium citrate, pH 7.2) or additionally in the presence of 50% formamide, for example 42°C in 5 x SSC, 50% formamide. Advantageously, the hybridization conditions for DNA:DNA hybrids are 0.1 x SSC and temperatures between about 200C to 45°C, preferably between about 300C to 45°C. For DNA:RNA hybrids the hybridization conditions are advantageously 0.1 x SSC and temperatures between about 300C to 55°C, preferably between about 45°C to 55°C. These stated temperatures for hybridization are examples of calculated melting temperature values for a nucleic acid with a length of approx. 100 nucleotides and a G + C content of 50% in the absence of formamide. The experimental conditions for DNA hybridization are described in relevant genetics textbooks, for example Sambrook et al., 1989, and can be calculated using formulae that are known by a person skilled in the art, for example depending on the length of the nucleic acids, the type of hybrids or the G + C content. A person skilled in the art can obtain further information on hybridization from the following textbooks: Ausubel et al. (eds), 1985, Current Protocols in Molecular Biology, John Wiley & Sons, New York; Hames and Higgins (eds), 1985, Nucleic Acids Hybridization: A Practical Approach, IRL Press at Oxford University Press, Oxford; Brown (ed), 1991 , Essential Molecular Biology: A Practical Approach, IRL Press at Oxford University Press, Oxford.
"Hybridization" can in particular be carried out under stringent conditions. Such hybridization conditions are for example described in Sambrook, J., Fritsch, E. F., Maniatis, T., in: Molecular Cloning (A Laboratory Manual), 2nd edition, Cold Spring Harbor Laboratory Press, 1989, pages 9.31-9.57 or in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
"Stringent" hybridization conditions mean in particular: Incubation at 42°C overnight in a solution consisting of 50% formamide, 5 x SSC (750 mM NaCI, 75 mM
tri-sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt Solution, 10% dextran sulfate and 20 g/ml denatured, sheared salmon sperm DNA, followed by washing of the filters with 0.1 x SSC at 65°C.
The invention also relates to derivatives of the concretely disclosed or derivable nucleic acid sequences.
Thus, further nucleic acid sequences according to the invention can be derived from the sequences specifically disclosed herein and can differ from it by addition, substitution, insertion or deletion of individual or several nucleotides, and furthermore code for polypeptides with the desired profile of properties. The invention also encompasses nucleic acid sequences that comprise so-called silent mutations or have been altered, in comparison with a concretely stated sequence, according to the codon usage of a special original or host organism, as well as naturally occurring variants, e.g. splicing variants or allelic variants, thereof.
It also relates to sequences that can be obtained by conservative nucleotide substitutions (i.e. the amino acid in question is replaced by an amino acid of the same charge, size, polarity and/or solubility).
The invention also relates to the molecules derived from the concretely disclosed nucleic acids by sequence polymorphisms. These genetic polymorphisms can exist between individuals within a population owing to natural variation. These natural variations usually produce a variance of 1 to 5% in the nucleotide sequence of a gene.
Derivatives of nucleic acid sequences according to the invention mean for example allelic variants, having at least 60% homology at the level of the derived amino acid, preferably at least 80% homology, quite especially preferably at least 90% homology over the entire sequence range (regarding homology at the amino acid level, reference should be made to the details given above for the polypeptides). Advantageously, the homologies can be higher over partial regions of the sequences.
Furthermore, derivatives are also to be understood to be homologues of the nucleic acid sequences according to the invention, for example animal, plant, fungal or bacterial homologues , shortened sequences, single-stranded DNA or RNA of the coding and noncoding DNA sequence. For example, homologues have, at the DNA level, a homology of at least 40%, preferably of at least 60%, especially preferably of at least 70%, quite especially preferably of at least 80% over the entire DNA region given in a sequence specifically disclosed herein.
Moreover, derivatives are to be understood to be, for example, fusions with promoters. The promoters that are added to the stated nucleotide sequences can be modified by at least one nucleotide exchange, at least one insertion, inversion and/or deletion, though without impairing the functionality or efficacy of the promoters. Moreover, the efficacy of the promoters can be increased by altering their sequence or can be exchanged completely with more effective promoters even of organisms of a different genus.
3.3 Preparation of functional mutants The skilled reader is also aware of methods of generating functional mutants.
Depending on the technique applied, a skilled reader may generate arbitrary or directed mutations in genes or non-coding nucleic acid regions (which, for example, may be of importance for regulating gene expression) and, afterwards, may generate suitable gene libraries. The molecular biological method required therefore all well known in the art, and, for example, described by Sambrook and Russell, Molecular Cloning. 3. Edition, Cold Spring Harbor Laboratory Press 2001.
Methods of modifying genes and consequently of modifying the encoded proteins are well known to the skilled reader, as for example
- site-specific mutagenesis wherein single or multiple nucleotides of a gene are specifically replaced (T rower MK (Ed.) 1996; In vitro mutagenesis protocols. Humana
Press, New Jersey),
- saturation mutagenesis, wherein at any position of a gene the codon of any amino acid may be exchanged or added (Kegler-Ebo DM, Docktor CM, DiMaio D (1994) Nucleic Acids Res 22:1593; Barettino D, Feigenbutz M, Valcarel R, Stunnenberg HG (1994) Nucleic Acids Res 22:541 ; Barik S (1995) MoI Biotechnol 3:1 ),
- error-prone polymerase chain reaction( PCR), wherein nucleotide sequences are mutated via the action of an incorrectly functioning DNA-polymerase (Eckert KA, Kunkel TA (1990) Nucleic Acids Res 18:3739);
- SeSaM method (Sequence Saturation Method), wherein preferred substitutions are avoided by the polymerase (Schenk et al., Biospektrum, Vol. 3, 2006, 277-279)
- Passaging of genes in mutator-strains, showing an increased occurrence of mutations of nucleotide sequences, for example in view of a defective DNA-repair mechanism (Greener A, Callahan M, Jerpseth B (1996) An efficient random mutagenesis technique
using an E.coli mutator strain. In: Trower MK (Hrsg.) In vitro mutagenesis protocols. Humana Press, New Jersey), or
- DNA-Shuffling, wherein a pool of closely related genes is formed and digested and wherein the fragments are used as templates for a PCR reaction, and wherein full- length mosaic genes are formed (Stemmer WPC (1994) Nature 370:389; Stemmer WPC (1994) Proc Natl Acad Sci USA 91 :10747).
By applying the so-called directed evolution technique (see for example Reetz MT und Jaeger K-E (1999), Topics Curr Chem 200:31 ; Zhao H, Moore JC, Volkov AA, Arnold FH (1999), Methods for optimizing industrial enzymes by directed evolution, In: Demain AL, Davies JE (Hrsg.) Manual of industrial microbiology and biotechnology. American Society for Microbiology) a skilled reader will be able to specifically prepare functional mutants in large scale. In a first step libraries of a specific protein are generated, for example, by applying any one of the above mentioned methods. Afterwards said libraries are expressed, for example by applying bacteria or phage display systems.
Those genes expressing functional mutants showing the desired feature profile may be selected and subjected to further mutation. The steps of mutation and selection or screening may be repeated iteratively until one of the obtained mutants shows the desired feature profile. By the iterative approach a limited number of mutations, as for example 1 to 5 mutations, may be performed and their influence on the enzyme feature at issue may be evaluated and further improved mutants may be selected stepwise. Said selected mutant may then be subjected to a further mutation in substantially the same may. The number of single mutants to be evaluated may be reduced significantly in this way. The teaching of the present invention provide important information as regards structure and sequence of the enzyme/ protein at issue, based on which it should be possible to generate further enzymes/proteins with the desired modified feature profile. In particular, so-called hot spots, i.e. sequence regions may be defined, which potentially may be suited for further mutation in order to modify or generate a desired feature of the enzyme/protein.
3.4 Constructs according to the invention
The invention also relates to expression constructs, containing, under the genetic control of regulatory nucleic acid sequences, a nucleic acid sequence coding
for a polypeptide or fusion protein according to the invention; as well as vectors comprising at least one of these expression constructs.
"Expression unit" means, according to the invention, a nucleic acid with expression activity, which comprises a promoter as defined herein and, after functional association with a nucleic acid that is to be expressed or a gene, regulates the expression, i.e. the transcription and the translation of this nucleic acid or of this gene. In this context, therefore, it is also called a "regulatory nucleic acid sequence". In addition to the promoter, other regulatory elements may be present, e.g. enhancers.
"Expression cassette" or "expression construct" means, according to the invention, an expression unit, which is functionally associated with the nucleic acid that is to be expressed or the gene that is to be expressed. In contrast to an expression unit, an expression cassette thus comprises not only nucleic acid sequences which regulate transcription and translation, but also the nucleic acid sequences which should be expressed as protein as a result of the transcription and translation. The terms "expression" or "overexpression" describe, in the context of the invention, the production or increase of intracellular activity of one or more enzymes in a microorganism, which are encoded by the corresponding DNA. For this, it is possible for example to insert a gene in an organism, replace an existing gene by another gene, increase the number of copies of the gene or genes, use a strong promoter or use a gene that codes for a corresponding enzyme with a high activity, and optionally these measures can be combined.
Preferably such constructs according to the invention comprise a promoter 5'- upstream from the respective coding sequence, and a terminator sequence 3'- downstream, and optionally further usual regulatory elements, in each case functionally associated with the coding sequence.
A "promoter", a "nucleic acid with promoter activity" or a "promoter sequence" mean, according to the invention, a nucleic acid which, functionally associated with a nucleic acid that is to be transcribed, regulates the transcription of this nucleic acid.
"Functional" or "operative" association means, in this context, for example the sequential arrangement of one of the nucleic acids with promoter activity and of a nucleic acid sequence that is to be transcribed and optionally further regulatory elements, for example nucleic acid sequences that enable the transcription of nucleic acids, and for example a terminator, in such a way that each of the regulatory elements can fulfill its function in the transcription of the nucleic acid sequence. This does not
necessarily require a direct association in the chemical sense. Genetic control sequences, such as enhancer sequences, can also exert their function on the target sequence from more remote positions or even from other DNA molecules. Arrangements are preferred in which the nucleic acid sequence that is to be transcribed is positioned behind (i.e. at the 3' end) the promoter sequence, so that the two sequences are bound covalently to one another. The distance between the promoter sequence and the nucleic acid sequence that is to be expressed transgenically can be less than 200 bp (base pairs), or less than 100 bp or less than 50 bp. Apart from promoters and terminators, examples of other regulatory elements that may be mentioned are targeting sequences, enhancers, polyadenylation signals, selectable markers, amplification signals, replication origins and the like. Suitable regulatory sequences are described for example in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Nucleic acid constructs according to the invention comprise in particular sequences selected from those, specifically mentioned herein or derivatives and homologues thereof, as well as the nucleic acid sequences that can be derived from amino acid sequences specifically mentioned herein which are advantageously associated operatively or functionally with one or more regulating signal for controlling, e.g. increasing, gene expression.
In addition to these regulatory sequences, the natural regulation of these sequences can still be present in front of the actual structural genes and optionally can have been altered genetically, so that natural regulation is switched off and the expression of the genes has been increased. The nucleic acid construct can also be of a simpler design, i.e. without any additional regulatory signals being inserted in front of the coding sequence and without removing the natural promoter with its regulation. Instead, the natural regulatory sequence is silenced so that regulation no longer takes place and gene expression is increased.
A preferred nucleic acid construct advantageously also contains one or more of the aforementioned enhancer sequences, functionally associated with the promoter, which permit increased expression of the nucleic acid sequence. Additional advantageous sequences, such as other regulatory elements or terminators, can also be inserted at the 3' end of the DNA sequences. One or more copies of the nucleic acids according to the invention can be contained in the construct. The construct can
also contain other markers, such as antibiotic resistances or auxotrophy- complementing genes, optionally for selection on the construct.
Examples of suitable regulatory sequences are contained in promoters such as cos-, tac-, trp-, tet-, trp-tet-, Ipp-, lac-, Ipp-lac-, laclq"' T7-, T5-, T3-, gal-, trc-, ara-, rhaP (rhaPBAD)SP6-, Iambda-PR- or in the Iambda-PL promoter, which find application advantageously in Gram-negative bacteria. Other advantageous regulatory sequences are contained for example in the Gram-positive promoters ace, amy and SPO2, in the yeast or fungal promoters ADC1 , MFalpha, AC, P-60, CYC1 , GAPDH, TEF, rp28, ADH. Artificial promoters can also be used for regulation. For expression, the nucleic acid construct is inserted in a host organism advantageously in a vector, for example a plasmid or a phage, which permits optimum expression of the genes in the host. In addition to plasmids and phages, vectors are also to be understood as meaning all other vectors known to a person skilled in the art, e.g. viruses, such as SV40, CMV, baculovirus and adenovirus, transposons, IS elements, phasmids, cosmids, and linear or circular DNA. These vectors can be replicated autonomously in the host organism or can be replicated chromosomally. These vectors represent a further embodiment of the invention.
Suitable plasmids are, for example in E. coli, pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHS1 , pKK223-3, pDHE19.2, pHS2, pPLc236, pMBL24, pLG200, pUR290, plN-IN113-B 1 , λgt1 1 or p Bd C I ; i n nocard ioform actinomycetes pJAM2; in Streptomyces plJ101 , plJ364, plJ702 or plJ361 ; in bacillus pUB110, pC194 or pBD214; in Corynebacterium pSA77 or pAJ667; in fungi pALS1 , plL2 or pBB1 16; in yeasts 2alphaM, pAG-1 , YEp6, YEp13 or pEMBLYe23 or in plants pLGV23, pGHIac+, pBIN19, pAK2004 or pDH51. The aforementioned plasmids represent a small selection of the possible plasmids. Other plasmids are well known to a person skilled in the art and will be found for example in the book Cloning Vectors (Eds. Pouwels P. H. et al. Elsevier, Amsterdam-New York-Oxford, 1985, ISBN 0 444 904018). Further suitable plasmid are also mentioned in the experimental part. In a further embodiment of the vector, the vector containing the nucleic acid construct according to the invention or the nucleic acid according to the invention can be inserted advantageously in the form of a linear DNA in the microorganisms and integrated into the genome of the host organism through heterologous or homologous
recombination. This linear DNA can comprise a linearized vector such as plasmid or just the nucleic acid construct or the nucleic acid according to the invention.
For optimum expression of heterologous genes in organisms, it is advantageous to alter the nucleic acid sequences in accordance with the specific codon usage employed in the organism. The codon usage can easily be determined on the basis of computer evaluations of other, known genes of the organism in question.
The production of an expression cassette according to the invention is based on fusion of a suitable promoter with a suitable coding nucleotide sequence and a terminator signal or polyadenylation signal. Common recombination and cloning techniques are used for this, as described for example in T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989) as well as in TJ. Silhavy, M. L. Berman and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and in Ausubel, F. M. et al., Current Protocols in Molecular Biology, Greene Publishing Assoc, and Wiley lnterscience (1987).
The recombinant nucleic acid construct or gene construct is inserted advantageously in a host-specific vector for expression in a suitable host organism, to permit optimum expression of the genes in the host. Vectors are well known to a person skilled in the art and will be found for example in "Cloning Vectors" (Pouwels P. H. et al., Publ. Elsevier, Amsterdam-New York-Oxford, 1985).
3.5 Hosts that can be used according to the invention
Depending on the context, the term "microorganism" means the starting microorganism (wild-type) or a genetically modified microorganism according to the invention, or both.
The term "wild-type" means, according to the invention, the corresponding starting microorganism, and need not necessarily correspond to a naturally occurring organism.
By means of the vectors according to the invention, recombinant microorganisms can be produced, which have been transformed for example with at least one vector according to the invention and can be used for the fermentative production according to the invention.
Advantageously, the recombinant constructs according to the invention, described above, are inserted in a suitable host system and expressed. Preferably,
common cloning and transfection methods that are familiar to a person skilled in the art are used, for example co-precipitation, protoplast fusion, electroporation, retroviral transfection and the like, in order to secure expression of the stated nucleic acids in the respective expression system. Suitable systems are described for example in Current Protocols in Molecular Biology, F. Ausubel et al., Publ. Wiley Interscience, New York 1997, or Sambrook et al. Molecular Cloning: A Laboratory Manual. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
The parent microorganisms are typically those which have the ability to produce glutaconate, in particular (E)-glutaconate, from glucose and or glutamate.
Preferably they are bacteria, in particular of the orders Clostridials and Fusobacteriales. In particular, the species A. fermentans (DSM 20731 ), C. symbiosium (DSM 934), C. sporospaeroides (DSM 1294), P. assacharolyticus (ATCC 14963) and F. nucleatum subsp. nucleatum (DSM 15643) have to be mentioned. ATCC designates American type strain culture collection, and DSM designates
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.
The host organism or host organisms according to the invention preferably contain at least one of the nucleic acid sequences, nucleic acid constructs or vectors described in this invention, which code for an enzyme activity according to the above definition.
3.6 Fermentative production of glutaconate products of the invention
The invention relates to methods for the fermentative production of glutaconate and related compounds of formula (I). The recombinant microorganisms as used according to the invention can be cultivated continuously or discontinuously in the batch process or in the fed batch or repeated fed batch process. A review of known methods of cultivation will be found in the textbook by Chmiel (Bioprozesstechnik 1. Einfϋhrung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991 )) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).
The culture medium that is to be used must satisfy the requirements of the particular strains in an appropriate manner. Descriptions of culture media for various microorganisms are given in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D. C, USA, 1981 ).
These media that can be used according to the invention generally comprise one or more sources of carbon, sources of nitrogen, inorganic salts, vitamins and/or trace elements.
Preferred sources of carbon are sugars, such as mono-, di- or polysaccharides. Very good sources of carbon are for example glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose.
Sugars can also be added to the media via complex compounds, such as molasses, or other by-products from sugar refining. It may also be advantageous to add mixtures of various sources of carbon. Other possible sources of carbon are oils and fats such as soybean oil, sunflower oil, peanut oil and coconut oil, fatty acids such as palmitic acid, stearic acid or linoleic acid, alcohols such as glycerol, methanol or ethanol and organic acids such as acetic acid or lactic acid.
Sources of nitrogen are usually organic or inorganic nitrogen compounds or materials containing these compounds. Examples of sources of nitrogen include ammonia gas or ammonium salts, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate or ammonium nitrate, nitrates, urea, amino acids or complex sources of nitrogen, such as corn-steep liquor, soybean flour, soybean protein, yeast extract, meat extract and others. The sources of nitrogen can be used separately or as a mixture. Inorganic salt compounds that may be present in the media comprise the chloride, phosphate or sulfate salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron.
Inorganic sulfur-containing compounds, for example sulfates, sulfites, dithionites, tetrathionates, thiosulfates, sulfides, but also organic sulfur compounds, such as mercaptans and thiols, can be used as sources of sulfur.
Phosphoric acid, potassium dihydrogenphosphate or dipotassium hydrogenphosphate or the corresponding sodium-containing salts can be used as sources of phosphorus.
Chelating agents can be added to the medium, in order to keep the metal ions in solution. Especially suitable chelating agents comprise dihydroxyphenols, such as catechol or protocatechuate, or organic acids, such as citric acid.
The fermentation media used according to the invention may also contain other growth factors, such as vitamins or growth promoters, which include for example biotin, riboflavin, thiamine, folic acid, nicotinic acid, pantothenate and pyridoxine. Growth
factors and salts often come from complex components of the media, such as yeast extract, molasses, corn-steep liquor and the like. In addition, suitable precursors can be added to the culture medium. The precise composition of the compounds in the medium is strongly dependent on the particular experiment and must be decided individually for each specific case. Information on media optimization can be found in the textbook "Applied Microbiol. Physiology, A Practical Approach" (Publ. P.M. Rhodes, P. F. Stanbury, IRL Press (1997) p. 53-73, ISBN 0 19 963577 3). Growing media can also be obtained from commercial suppliers, such as Standard 1 (Merck) or BHI (Brain heart infusion, DIFCO) etc. All components of the medium are sterilized, either by heating (20 min at 2.0 bar and 1210C) or by sterile filtration. The components can be sterilized either together, or if necessary separately. All the components of the medium can be present at the start of growing, or optionally can be added continuously or by batch feed.
The temperature of the culture is normally between 15°C and 45°C, preferably 25°C to 400C and can be kept constant or can be varied during the experiment. The pH value of the medium should be in the range from 5 to 8.5, preferably around 7.0. The pH value for growing can be controlled during growing by adding basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water or acid compounds such as phosphoric acid or sulfuric acid. Antifoaming agents, e.g. fatty acid polyglycol esters, can be used for controlling foaming. To maintain the stability of plasmids, suitable substances with selective action, e.g. antibiotics, can be added to the medium. Oxygen or oxygen-containing gas mixtures, e.g. the ambient air, are fed into the culture in order to maintain aerobic conditions. The temperature of the culture is normally from 200C to 45°C. Culture is continued until a maximum of the desired product has formed. This is normally achieved within 10 hours to 160 hours.
The cells can be disrupted optionally by high-frequency ultrasound, by high pressure, e.g. in a French pressure cell, by osmolysis, by the action of detergents, lytic enzymes or organic solvents, by means of homogenizers or by a combination of several of the methods listed.
3.7 Product isolation
The methodology of the present invention can further include a step of recovering glutaconate or related compounds. The term "recovering" includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the
compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (e.g., anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (e.g., with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), distillation, dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For example glutaconate can be recovered from culture media by first removing the microorganisms. The remaining broth is then passed through or over a cation exchange resin to remove unwanted cations and then through or over an anion exchange resin to remove unwanted inorganic anions and organic acids.
3.8 Polymers In another aspect, the present invention provides a process for the production of polyesters or polyamides (e.g. nylon ® or related polymers) comprising a step as mentioned above for the production of glutaconate compounds. The glutaconate compound is reacted in a known manner with di-, tri- or polyamines to get polyamides or with di-, tri- or polyols to obtain polyesters. For example, the glutaconate-type compound is reacted with polyamine or polyol containing 4 to 10 carbons.
In another aspect, the present invention provides method of preparing a polymer, in particular copolymers, which method comprises preparing a mono-unsaturated dicarboxylic acid compounds of the general formula (I) as defined above a by method as described therein, isolating said compound; and polymerizing said compound with at least one suitable unsaturated polymerizable monomer, preferably in the presence of a polymerization initiator, like for example sodiumperoxide disulfate (NAPS) as radical initiator.
As non-limiting examples of sutable co-monomers for performing the above polymerization reactions there may be mentioned:
polyols such as ethylene glycol, propylene glycol, glycerol, polyglycerols having 2 to 8 glycerol units, erythritol, pentaerythritol, and sorbitol.
polyamines, such as diamines, triamines and tetraamines, like ethylene diamine, propylene diamine, butylene diamine, neopentyl diamine, hexamethylene diamine, octamethylene diamine, diethylene triamine, triethylene tetramine, tetraethylene pentamine, dipropylene triamine, tripropylene tetramine, dihexamethylene triamine, aminopropylethylenediamine and bisaminopropylethylenediamine. Suitable polyamines are also polyalkylenepolyamines. The higher polyamines can be present in a mixture with diamines. Useful diamines include for example 1 ,2-diaminoethane, 1 ,3- diaminopropane, 1 ,4-diaminobutane, 1 ,5-diaminopentane, 1 ,6-diaminohexane, 1 ,8- diaminooctane. alkenes, in particular C2-Ci2-alkenes which are monounsaturated linear or branched hydrocarbons having from 2 to 12 carbon atoms, as for example ethylene, 1- or 2-propylene, 1-, 2- and 3-butylene, 2-methyl-propylen, 1-, 2-, 3- and 4-pentenylene, 1-, 2-, 3-, 4- and 5-hexylene, 1-, 2-, 3-, 4-, 5- and 6-heptylene, or 1-, 2-, 3-, 4-, 5-, 6- and 7-octylene, 1-decene, 1-dodecene;and also their constitutional isomers. mono-unsaturated C3-C8-carboxylic acids, like acrylic acid or (d-C7-alkyl) acrylic acids, vinylacetic acid, crotonic acid, fumaric acid, maleic acid, itaconic acid esters of monoethylenically unsaturated C3-C8 monocarboxylic acids with C1-C20 alkanols, C5-C8 cycloalkanol, phenyl-Ci-C4 alkanols or phenoxy-Ci-C4 alkanols, examples being esters of acrylic acid with C1-C20 alkanols, such as methyl acrylate, ethyl acrylate, n-butyl acrylate, 2-butyl acrylate, isobutyl acrylate, tert-butyl acrylate, 2- ethylhexyl acrylate, decyl acrylate, lauryl acrylate and stearyl acrylate, esters of acrylic acid with C5-Ci0 cycloalkanols such as cyclohexyl acrylate, esters of acrylic acid with phenyl-Ci-C4 alkanols such as benzyl acrylate, 2-phenylethyl acrylate and 1- phenylethyl acrylate, esters of acrylic acid with phenoxy-Ci-C4 alkanols such as 2- phenoxyethyl acrylate, esters of methacrylic acid with CrC20 alkanols, preferably d- Cio alkanols, such as methyl methacrylate, ethyl methacrylate, n-butyl methacrylate, 2- butyl methacrylate, isobutyl methacrylate, tert-butyl methacrylate, 2-ethylhexyl methacrylate, decyl methacrylate, lauryl methacrylate and stearyl methacrylate, esters of methacrylic acid with C5-Ci0 cycloalkanols, such as cyclohexyl methacrylate, esters of methacrylic acid with phenyl-Ci-C4 alkanols, such as benzyl methacrylate, 2-phenylethyl methacrylate and 1-phenylethyl methacrylate, and esters of methacrylic acid with phenoxy-Ci-C4 alkanols, such as 2-phenoxyethyl methacrylate; diesters of monoethylenically unsaturated C4-C8 dicarboxylic acids with CrC20 alkanols, such as diesters of maleic acid or of fumaric acid with CrC20 alkanols,
examples being dimethyl maleate, diethyl maleate, di-n-butyl maleate, dimethyl fumarate, diethyl fumarate, and di-n-butyl fumarate;
C1-C20 alkylamides and di-Ci-C2o alkylamides of monoethylenically unsaturated C3-C8 monocarboxylic acids, especially the C1-C20 alkylamides and di-Ci-C2o alkylamides of acrylic acid and of methacrylic acid, for example, amides of monoethylenically unsaturated carboxylic acids, such as acrylamide or methacrylamide,
anhydrides of monoethylenically unsaturated monocarboxylic and dicarboxylic acids having 3 to 8 C atoms, such as acrylic acid anhydride, methacrylic acid anhydride, maleic anhydride or itaconic anhydride,
hydroxyl-C2-C4 alkyl esters of monoethylenically unsaturated monocarboxylic or dicarboxylic acids having 3 to 8 C atoms, such as 2-hydroxyethyl acrylate, 2-hydroxypropyl acrylate, 3-hydroxypropyl acrylate, 2-hydroxybutyl acrylate, 4-hydroxybutyl acrylate, 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, 3-hydroxypropyl methacryl a t e , 2-hydroxybutyl methacrylate, 4-hydroxybutyl methacrylate,
monoethylenically unsaturated sulfonic acids and their salts, examples being vinylsulfonic acid, allylsulfonic acid, methallylsulfonic acid, styrenesulfonic acid, 2- acrylamido-2-methylpropanesulfonic acid, 2-methacrylamido-2-methylpropanesulfonic acid, 2-acrylamidoethanesulfonic acid, 2-methacrylamidoethanesulfonic acid, 2-acryloyloxyethanesulfonic acid, 2-methacryloyloxyethanesulfonic acid, 3-acryloyloxypropanesulfonic acid and 2-methacryloyloxypropanesulfonic acid,
monoethylenically unsaturated nitriles having 3 to 5 C atoms, such as acrylonitrile and methacrylonitrile,
N-vinyl heterocycles such as N-vinylpyrrolidone, N-vinylcaprolactam, N- vinylimidazole, and
monoethylenically unsaturated compounds having at least one PoIy-C2-C4 alkylene oxide group, examples being vinyl ethers and allyl ethers of poly-C2-C4 alkylene glycols or C1-C10 alkyl-poly-C2-C4 alkylene glycols, esters of monoethylenically unsaturated monocarboxylic and dicarboxylic acids having 3 to 8 C atoms with poly-C2-
C4 alkylene glycols or C1-C10 alkyl-poly-C2-C4 alkylene glycols, amides of monoethylenically unsaturated monocarboxylic and dicarboxylic acids having 3 to 8 C atoms with poly-C2-C4 alkylene glycol amines or C1-C10 alkyl-poly-C2-C4 alkylene glycol amines
ethylenically unsaturated compounds having at least one having a basic nitrogen or quaternized nitrogen atom such as diallyldimethyl ammonium chloride, N-methyl-N- vinylimidazolium salts such as the chloride, sulfate or methosulfate, N-(2- (dimethylamino)ethyl) acrylamide, 2-(N,N-dimethylamino)ethyl acrylate,
2-(N,N-dimethylamino)ethyl methacrylate, 2-(N,N-dimethylamino)ethylacrylamide, 3-(N,N-dimethylamino)propylacrylamide, 3-(N,N-dimethylamino)propylmethacrylamide, 2-(N,N-dimethylamino)ethylmethacrylamide, 2-(N,N,N-trimethylammonio)ethyl acrylate chloride, 2-(N,N,N-trimethylammonio)ethyl methacrylate chloride, 2-(N,N,N-trimethyl- ammonio)ethylmethacrylamide chloride, 3-(N,N,N-trimethylammonio)propylacrylamide chloride, 3-(N, N, N-trimethylammonio)propylmethacrylamide chloride, 2-(N,N,N-trimethylammonio)ethylacrylamide chloride, and the corresponding sulfates and methyl sulfates.
vinyl aromatic monomers, such as styrene, α-methylstyrene, vinyltoluene, tert- butylstyrene, vinylpyridines;
vinyl and allyl esters of aliphatic carboxylic acids having 1 to 20 C atoms, examples being vinyl acetate, vinyl propionate, vinyl butyrate, vinyl hexanoate, vinyl laurate, and vinyl stearate;
conjugated diolefins such as butadiene and isoprene, and
halovinyl compounds such as chloroethene (vinyl chloride), 1 ,1-dichloroethene (vinylidene chloride), fluoroethene, 1 ,1-difluoroethene, and tetrafluoroethene.
Unless otherwise stated akyl mar refer to Ci-C7-alkyl and may be methyl, ethyl, propyl, isopropyl, n-butyl, 2-butyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1 ,2-dimethylpropyl, 1 ,1-dimethylpropyl, 2,2-dimethyl- propyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,3-dimethylbutyl, 1 ,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-di methylbutyl , 1 , 1 ,2-trimethylpropyl,
1 ,2,2-trimethylpropyl, 1-ethylbutyl, 2-ethylbutyl, 1-ethyl-2-methylpropyl, n-heptyl, 2-heptyl, 3-heptyl, 2-ethylpentyl, 1-propylbutyl etc.
The following examples only serve to illustrate the invention. The numerous possible variations that are obvious to a person skilled in the art also fall within the scope of the invention.
Experimental Part
Unless otherwise stated the following experiments have been performed by applying standard equipment, methods, chemicals, and biochemicals as used in genetic engineering, fermentative production of chemical compounds by cultivation of microorganisms and in the analysis and isolation of products. See also Sambrook et al , and Chmiel et al as cited herein above.
Materials and methods
a) Materials All chemicals and biochemicals were from Roche (Mannheim, Germany), Sigma
(Deisenhofen, Germany), and AppliChem. The enzymes for DNA manipulation, DNA size markers, protein molecular mass markers and the molecular mass standard for SDS/PAGE were from Fermentas GmbH (St. Leon-Rot, Germany). E. coli strain BL21 was from Stratagene. Sequencing primers were purchased from MWG-Biotech AG (Ebersberg, Germany). Coenzyme A is from MP Biomedicals. CoA-esters of glutaric and acetic acids were prepared from the corresponding anhydrides (Simon, E.J & Shemin, D. (1953) J. Am. Chem. Soc. 75, 2530).
b) Organisms and growth E. coli DH5Ci, used for cloning, and E. coli BL21 , used for expression were grown under anaerobic conditions at room temperature on Standard I medium (1.5% peptone, 0.3% yeast extract, 100 mM NaCI, 5 mM glucose; Merck, Darmstadt), supplemented with 50 mM MOPS, 3 mM cysteine hydrochloride, 10 mM Na-glutamate, riboflavin and FeCI2, at various concentrations.
c) Enzyme activity assay
2-Hydroxyglutarate dehydrogenase activity was measured at ambient temperature in cuvettes of 0.5 ml total volume containing 0.1 M Tris/HCI pH 8.0, 0.2
mM NADH and 2-hydroxyglutarate dehydrogenase at room temperature. After addition of 1 mM α-ketoglutarate, the absorbance decrease of NADH was monitored at 340 nm (ε = 6.3 mM-1 cm-1 ) (Bresser J (1997) (R)-2-Hydroxyglutarat-Dehydrogenase aus Acidaminococcus fermentans. PhD Thesis, Philipps-Universita t Marburg, Germany; Martins BM, Macedo-Ribeiro S, Bresser J , Buckel W, Messerschmidt A (2005) Structural basis for stereo-specific catalysis in NAD+-dependent (R)-2-hydroxyglutarate dehydrogenase from Acidaminococcus fermentans. Febs J 272:269-281 )-
Glutaconate CoA-transferase activity assay was performed aerobically at room temperature. The increase of absorbance was followed at 412 nm, Δε = 14 mM-1 cm-1. Reagents used in assay are 0.1 M potassium phosphate pH 7.0, 0.2 M sodium acetate, 1 m M oxaloacetate, 1 m M 5,5'-dithiobis(2-nitrobenzoate) (DTNB), 20 μg citrate synthase, 0.1 mM glutaryl-CoA, total volume 0.5 ml (Buckel W, Dorn U, Semmler R (1981 ) Glutaconate CoA-transferase from Acidaminococcus fermentans. E u r J Biochem 1 18:315-321 ; Jacob U, Mack M, Clausen T, Huber R, Buckel W, Messerschmidt A (1997) Glutaconate CoA-transferase from Acidaminococcus fermentans: the crystal structure reveals homology with other CoA-transferases. Structure 5:415-426).
2-Hydroxyglutaryl-CoA dehydratase activity was measured under anoxic conditions at ambient temperature in cuvettes of 0.5 ml total volume containing 50 mM Mops/KOH pH 7.0, 10 mM dithiothreitol, 5 mM MgCI2, 0.1 mM dithionite, 0.4 mM ATP, and 2-hydroxyglutarate dehydrogenase with activator. After 10 minutes of incubation the reaction was started with 2 mM acetyl-CoA and 2 mM (R)-2-hydroxyglutarate. The increase of absorbance due to the formation of glutaconyl-CoA was followed at 290 nm (ε = 2.2 mM"1cm"1) (Kim J, Darley DJ, Buckel W, Pierik AJ (2008) An allylic ketyl radical intermediate in clostridial amino-acid fermentation. Nature 452:239-242).
Glutaconate was enzymatically determined with 2 mM acetyl-CoA, 50 mM potassium phosphate pH7.0, 0.25 mM NADPH, glutaconate and using a catalytic amount of enzymes glutaconate-CoA transferase, glutaconyl-CoA decarboxylase [3,5,6] and crotonyl-CoA carboxylase/reductase [9]. The formation of NADP+ was measured spectrophotometrically at 340 nm.
Glutaconate was also determined by HPLC at room temperature with UV detection at 210 nm using a C18 reverse-phase column in 20 mM sulfuric acid.
d) Other biochemical methods
Protein concentrations were determined using the Bio-Rad microassay with bovine serum albumin as standard. SDS-PAGE was done in a Mini Protein apparatus (Bio-Rad, Heidelberg, Germany). Proteins were stained with Coomassie brilliant blue (Serva, Heidelberg, Germany).
Example 1 : Cloning of genes
Cloning methods
Routine manipulation of DNA, PCR and construction of recombinant plasmids were performed as described in (Sambrook J & Russell DW (2001 ) Molecular Cloning: a Laboratory Manual, 3rd edn. Cold Spring. Harbor Laboratory Press, Cold Spring Harbor, NY). PfuUltra High-Fidelity DNA Polymerase (Stratagene, USA) was used for the PCR amplification of gctAB using the following primers containing the Ndel: 5'-ATGGT ACATATGTGAGT AAAG TAATGACGTTAAAAGACGCAATCG-3' (SEQ ID NO:39) and
Xhol: δ'-ATGGTACTCGAGTTATTTTGCTTCC GTGGGGA CCTGG-3' (SEQ ID NO:40) restriction sites.
The genes hgdH (2-hydroxyglutarate dehydrogenase) and gctAB (glutaconate CoA-transferase) from A. fermentans were subcloned into pACYCDuet-1 vector (Novagen) (SEQ ID NO:13) from pET-Duet-1 and pJF1 18HE, respectively (Fig. 2) (Fϋrste JP, Pansegrau W, Frank R, Blocker H, Scholz P, Bagdasarian M, Lanka E (1986) Molecular cloning of the plasmid RP4 primase region in a multi-host-range tacP expression vector).
For cloning of hgdAB (2-hydroxyglutaryl-CoA dehydratase) from C. symbiosum and its activator hgdC from A. fermentans the pASK-IBA3plus vector (IBA GmbH, Gottingen, Germany) (SEQ ID NO:14) was used (Fig. 3).
Ligation and transformation conditions for hgdH in pACYCDuet-1 vector
The gene hgdH in pASKIBA7+ (laboratory collection) was subcloned into pETDuet (same procedures as described below) and then transferred to pACYCDuet-
1 , which can express up to 8 genes (10 kb). Before ligation, pETDuet_hgdH and pACYCDuet-1 vector were separately treated with restriction enzymes BamHI and
EcoNI (Fermentas) for 1 h at 37°C (Table 1 ).
Table 1. Digestion with BamHI and EcoNI
The ligation reaction (Table 2) was performed at 23°C. After one hour T4 DNA ligase (Fermentas) was inactivated by incubation at 65°C for 10 minutes. The salts from the ligation mixture were removed by drop dialysis, using a 0.025 μm Millipore membrane, at ambient temperature for 30 minutes. Ligation mixture was added to 50μl competent E.coli DH5α cells and transferred to an Electroporation Cuvette (Molecular BioProducts). A pulse was given to the cuvette using the following settings: 25 μF, 1.8 kV and 200 Ohm. The cuvette was washed with 300 μl Standard I medium and transferred to a sterile 1 .5 ml Eppendorf tube. The transformation mixture was incubated for 1 h at 37°C and plated on a LB agar plate containing chloramphenicol (50 μg-ml"1). The agar plate was incubated overnight at 37°C. Ten white colonies were picked and separately incubated in Standard medium overnight at 37°C: DNA was extracted using the Fermentas kit and digested with BamHI and EcoNI. One out of three correct fragments was extracted from the gel and ligated with gctAB.
Ligation and transformation conditions for gctAB in pACYCDuet-1 vector, containing hgdH gene
The gctAB genes were treated with two restriction enzymes Ndel and Xhol, which recognition sites were introduced by PCR reaction (Tables 3 and 4). Also the pACYCDuet-1 vector containing the hgdH gene, pACYCDuet-1_hgdH, was treated with the same restriction enzymes (Table 5). The ligation reaction and transformation were performed under conditions, explained in Table 6.
Table 3. PCR reaction mixture
Table 4. PCR reaction conditions
Table 5. Protocol for di estion
Ligation and transformation conditions for hgdAB and its activator gene hgdC in pASK-IBA 3 vector
The activator hgdC was introduced in pASK-IBA 3 vector, containing hgdAB genes. Both DNA were separately treated with restriction enzymes Eco47lll and MIsI (Fermentas) for 1 h at 37° C (Table 7). After digestion the enzyme was inactivated by incubation at 65°C for 20 minutes. The salts were removed by drop dialysis as above, at ambient temperature for 30 minutes. To the salt-free reaction, containing pASK-IBA 3_hgdAB, was added 1 μl (1 u/μl) of Shrimp Alkaline Phosphatase (Fermentas), 2 μl of 10x Reaction buffer and incubated for 1 h at 37°C. The reaction was stopped by
heating at 65°C for 15 minutes. Ligation reaction (Table 8) and transformation were performed under the conditions explained above. Carbenicillin (100 μg-ml"1) replaced chloramphenicol as antibiotic.
Table 7. Digestion of hgdC and hgdAB
Gene expression The genes were transformed into modified E. coli BL21-CodonPlus(DE3). An overnight anaerobic preculture (100 ml) of a fresh single colony was used to inoculate 1 litre Standard I medium, described above, containing antibiotics (carbenicillin, 100 μg-ml"1; chloramphenicol, 50 μg-ml"1) and grown at the same conditions. When the culture reached OD578 = 0.2, gene expression was induced with isopropyl-1-thio-β-D- galactoside, IPTG (240 mg-liter"1) and anhydrotetracycline, AHT (200 μg-liter"1). Cells were harvested 3 hours after induction (at OD578 = 0.573), washed and suspended in 20 ml of buffer (50 mM MOPS, 5 mM MgCI2 and 2 mM DTT) under anoxic conditions. The induced E. coli cells were lysed by French press and cell debris was removed by ultracentrifugation at 100 000 g at 4°C for 1 hour.
Example 2: Fermentative production of glutaconate
The first step was the construction of a plasmid, which comprises the six genes of 2-hydroxyglutarate dehydrogenase (hgdH), glutaconate CoA-transferase (gctAB), and the activator of 2-hydroxyglutaryl-CoA dehydratase {hgdC) from A. fermentans as well as 2-hydroxyglutaryl-CoA dehydratase (hgdAB) from C. symbiosum (see example 1 ).
Determination of enzyme activities
In Table 9 the enzymatic activities are shown, which were measured in the recombinant E. coli strain.
Table 9. Enzymatic activities in the recombinant E. coli BL21
Determination of glutaconate
After growth, the glutaconate concentration in the medium was 0.30 ± 0.05 mM; when glutamate was omitted, the concentration decreased to 0.1 mM (Table 10). Hence, glutaconate indeed was produced indicating that the enzymes work also in vivo. However, the precursor of glutaconate is glutamate, either added as such or from peptone, rather than glucose as initially anticipated.
Table 10. The concentration of glutaconate depended on glutamate concentration
Addition of riboflavin and iron(ll) chloride in the Standard I medium, described above, increased the concentration of glutaconate (Table 1 1 ,12).
Table 11. Glutaconate in the medium
Table 12. Glutaconate in the cell free extract
The cell-free extract was prepared from 590 mg wet packed cells (approx. 118 mg dried cells) in 20 ml 50 mM MOPS pH 7.4. Assuming a volume of 2.5 ml/g dried cells (Brock M, Bucket W (2004) On the mechanism of action of the antifungal agent propionate. Eur J Biochem 271:3227-41) the internal concentration of glutaconate rises from 0.23 mM to 16 mM.
The original strain E. coli BL21 was grown and analysed under the same conditions as the recombinant strain and glutaconate was not detected.
Discussion
The data indicate that the recombinant E. coli strain indeed produced glutaconate. The substrate, however, is most likely glutamate rather than glucose, because glutamate enhanced the production glutaconate threefold. In the absence of the amino acid, the glutamate present in the peptone most likely is the precursor of glutaconate (Table 10). The use of glucose as precursor requires an electron acceptor, which cannot be oxygen because of the extreme sensitivity of the activator towards this agent (Buckel W, Golding BT (2006) Radical enzymes in anaerobes. Annu Rev Microbiol 60:27-49; , Kim J, Darley DJ, Buckel W, Pierik AJ (2008) An allylic ketyl radical intermediate in clostridial amino-acid fermentation. Nature 452:239-242). The iron requirement (Table 11 ) stems from the iron sulfur clusters in the dehydratase (HgdAB) and its activator (HgdC). The slight improvement with riboflavin is probably due to riboflavin-5'-phosphate (FMN) as prosthetic group of the dehydratase (Hans M, Buckel W, Bill E (2000) The iron-sulfur clusters in 2-hydroxyglutaryl-CoA dehydratase from Acidaminococcus fermentans. Biochemical and spectroscopic investigations. Eur J Biochem 267:7082-93) . Th e d ata further indicate that the concentration of glutaconate inside the cells (16 mM) is about 12-times higher than outside (1.4 mM). Therefore, the export of glutaconate, probably mediated by the succinate transporter (Janausch IG, Zientz E, Tran QH, Kroger A, Unden G.J2002) C4-dicarboxylate carriers
and sensors in bacteria. Biochim Biophys Acta. 1553:39-56), appears to limit the production of the dicarboxylic acid.
Example 3 : Evaluation of alternative substrates for the enzymes of the glutaconate production pathway
Non-limiting examples of further substrates are given below: a) 2-Hydroxyglutaryl-CoA dehydratase from Clostridium symbiosum and activator from Acidaminococcus fermentans
Table 13
(R)-2-Hydroxyglutaryl-CoA (E)-Glutaryl-CoA + H2O
(R)-2-Hydroxyadipoyl-CoA (£)-Hex-2-enedioyl-CoA + H2O
(£,£)-Muconyl-CoA + H2O (R,£)-2-Hydroxyhex-4-enedioyl-CoA
Scheme 1. Reactions catalysed by 2-hydroxyglutaryl-CoA dehydratase. It was assumed that the enzyme also exhibits also 2f?-specificity with substrates other than (R)-2-hydroxyglutaryl-CoA. (Anutthaman Parthasarathy and Wolfgang Buckel , unpublished)
b) (/?)-2-Hydroxyglutarate Dehydrogenase from A. fermentans
2-Hydroxymuconate (keto form, 2-oxo-hex-4-ene-dioate)
2-Oxoadipate
Scheme 2: Alternative substrates of (/?)-2-hydroxyglutarate dehydrogenase (NAD+). Most likely, both 2-oxoacids are reduced to the 2/?-enantiomers. Km and /ccat values were not determined yet. The enzyme is specific for NAD7NADH. No activity was observed with NADPH/2-oxoglutarate or NADH/oxaloacetate.
c) Glutaconate CoA-transferase from A. fermentans
This enzyme acts on (E)-glutaconate, glutarate, (R)-2-hydroxyglutarate, adipate; acetate, propionate, acrylate (Buckel, W., Dorn, U. & Semmler, R. 1981. Glutaconate CoA-transferase from Acidaminococcus fermentans. Eur. J. Biochem. 118, 315-321 ).
(R)-2-Hydroxyglutaryl-CoA, (E)-glutaconyl-CoA, muconyl-CoA, butynedioyl-CoA (acetylenedicarboxyl-CoA), 4-oxo-hex-2-eneoyl-CoA, 4-nitro-but-2-enoyl-CoA and (RS)-2-hydroxyadipoyl-CoA were prepared by this enzyme using acetyl-CoA and an excess of the neutralised acid. Since the R-emantiomers react faster than S, the product should be mainly (R)-2-hydroxyadipoyl-CoA (Anutthaman Parthasarathy and Wolfgang Buckel, unpublished).
Conclusion:
As all three enzymes of the glutaconate production pathway can also use the C-6 homologues, the production of hex-2-enedioic acid from 2-oxoadipic or 2-aminoadipic acid is also feasible.
The following examples illustrate applicability of glutaconate (a compound of formula I) as obtainable by a biocatalytic method of the present invention for the preparation of organic polymers.
Example 4: Preparation of glutaconic acid - acrylic acid copolymers
Copolymers from glutaconic acid and acrylic acid with molar ratios from 1 :1 to 1 :3
(glutaconic acid:acrylic acid) were synthesized via radical polymerization methods in water solution using sodium peroxide disulfate (NAPS) as radical initiator.
a) Glutaconic acid - co - acrylic acid (1 :1 mol) In a 500 ml reactor flask were placed glutaconic acid (10.00 g) and distilled water
(30.00 g). The mixture was stirred at 98°C under a nitrogen atmosphere for 15 minutes. A solution of NAPS (0.23 g) in distilled water (15.31 g) was added drop wise to the reactor over a period of 5 hours. 5 Minutes after the beginning of the addition of the initiator, a solution of acrylic acid (5.54 g) in distilled water (25.00 g) was also added drop wise to the reactor over a period of 4 hours. The temperature of the reaction was kept at 98°C. At the end of the initiator addition, the reaction was left at 98°C for other 2 hours and then cooled to room temperature.
A light yellow polymer solution was obtained with a solid content of 18.71 g. K- Value = 11 ,3 g (1wt% in deionized water).
b) Glutaconic acid - co - acrylic acid (1 :2 mol)
In a 500 ml reactor flask were placed glutaconic acid (10.00 g) and distilled water (30.00 g). The mixture was stirred at 98°C under a nitrogen atmosphere for 15 minutes. A solution of NAPS (0.32 g) in distilled water (20.76 g) was added drop wise to the reactor over a period of 6 hours. 5 Minutes after the beginning of the addition of the initiator, a solution of acrylic acid (11.08 g) in distilled water (33.23 g) was also added drop wise to the reactor, over a period of 5 hours. The temperature of the reaction was kept at 98°C. At the end of the initiator addition, the reaction was left at 98°C for other 2 hours and then cooled to room temperature. A light yellow polymer solution was obtained with a solid content of 20.59 g. K-
Value = 14,7 g (1wt% in deionized water).
c) Glutaconic acid - co - acrylic acid (1 :3 mol)
In a 500 ml reactor flask were placed glutaconic acid (10.00 g) and distilled water
(30.00 g). The mixture was stirred at 98°C under a nitrogen atmosphere for 15 minutes. A solution of NAPS (0.40 g) in distilled water (26.00 g) was added drop wise to the reactor over a period of 6 hours. 5 Minutes after the beginning of the addition of the initiator, a solution of acrylic acid (16.62 g) in distilled water (49.86 g) was also added drop wise to the reactor, over a period of 5 hours. The temperature of the reaction was kept at 98°C. At the end of the initiator addition, the reaction was left at 98°C for other 2 hours and then cooled to room temperature.
A light yellow polymer solution was obtained with a solid content of 20.90 g. K- Value = 17,20 g (1wt% in deionized water).
Mn = 13.800 Da; Mw = 55.000 Da
K-Value determination:
The K-values of the copolymer water solutions were determined in a deionized water solution at pH=7, T=25°C and with a polymer concentration of 1wt%, according to the procedure described by H. Fikenscher, in "Cellulose-Chemie" (1932), Band 13, 48-64, 71-74.
The documents as cited herein are all incorporated by reference.
HgdAB Hydroxyglutaryl-CoA Dehydratase (2 subunits)
HgdABD Hydroxyglutaryl-CoA Dehydratase (3 subunits)
HgdC Hydroxyglutaryl-CoA Dehydratase Activator
HgdH Hydroxyglutarate Dehydrogenase
GctAB Glutaconyl-CoA Transferase
A, B, C subunits alpha, beta and gamma
AS Amino acid sequence
NS Nucleic acid sequence
Claims
1. A biocatalytic method for the production of an unsaturated dicarboxylic acid compound of the general formula I
HOOC-CH=CH-X-COOH (I)
wherein
X represents a linear or branched, optionally unsaturated, optionally substituted hydrocarbon group
which method comprises;
converting a 2-hydroxy-substituted dicarboxylic acid compound of the general formula III
HOOC-C(OH)H-CH2-X-COOH (III)
wherein X is as defined above;
in a recombinant microorganism co-expressing the genes encoding a glutaconate CoA-transferase (E. C. 2.8.3.12) and a 2-hydroxyglutaryl-CoA dehydratase system, optionally in the presence of a coenzyme A source so that said compound of formula I is formed; and optionally isolating said compound of formula I in the form of a substantially pure stereoisomer or as a mixture of stereoisomers.
2. The method of claim 1 , wherein X is selected from (CH2)n, with n being an integer from 1 to 4, CH=CH, CH2-C(=O), or CH=C(OH)
3. The method of claim 1 or 2, wherein said 2-hydroxy-substituted dicarboxylic acid III is formed by said recombinant microorganism by a 2-hydroxyglutarate dehydrogenase (E. C. 1.1.1.-) catalyzed conversion of a 2-oxo-dicarboxylic acid compound of formula Il
HOOC-C(=O)-CH2-X-COOH (II)
wherein
X is defined above.
4. The method of claim 3, wherein the gene of said 2-hydroxyglutarate dehydrogenase is co-expressed by said recombinant microorganism.
5. The method of one of the preceding claims, wherein said oxo-dicarboxylic acid compound of formula Il is either added to or fermentatively produced by said recombinant microorganism.
6. The method of claim 5, wherein said microorganism is a glutamate and/or glucose metabolizing aerobic or anaerobic recombinant bacterium, and wherein said compound of formula Il is 2-oxoglutarate.
7. The method of claim 6, wherein said glutamate and/or glucose metabolizing recombinant bacterium is selected from the genus Escherichia.
8. The method of one of the preceding claims, wherein said 2-hydroxyglutaryl-CoA dehydratase system comprises a 2-hydroxyglutaryl-CoA dehydratase (E. C. 4.2.1.- ) and optionally an activator protein for said enzyme.
9. The method of one of the preceding claims, wherein said enzymes and activator protein are of prokaryotic or eukaryotic origin.
10. The method of claim 9, wherein said enzymes and activator originate from the same or different anaerobic bacterium having the ability to convert glutamate into glutaconate.
11. The method of claim 10, wherein said anaerobic bacterium is selected from bacteria of the genus Acidaminococcus, Clostridium, Fusobacterium, Peptostreptococcus
12. The method of claim 1 1 , wherein said anaerobic bacterium is Acidaminococcus fermentans, Clostridium symbiosum, Clostridium sporosphaeroides, Fusobacterium nucleatum including all subspecies, or Peptostreptococcus asaccharolyticus
13. The method of one of the preceding claims, wherein said a) 2-hydroxyglutarate dehydrogenase (HgdH) comprises an amino acid sequence of; SEQ ID NO: 2 or 16; or sequences having at least 50% identity thereto; b) glutaconate CoA transferase (GctAB) comprises an amino acid sequence of SEQ ID NO: 4 and/or 6; SEQ ID NO: 18 and/or 20; or SEQ ID NO: 22 and/or 24;or sequences having at least 50% identity thereto; c) 2-hydroxyglutaryl-CoA dehydratase comprises an amino acid sequence of SEQ ID NO: 8 and/or 10; SEQ ID NO: 26 and/or 28; or SEQ ID NO: 30, 32 and/or 34; or sequences having at least 50% identity thereto; d) and the activator protein (HdgC) of c) comprises an amino acid sequence of
SEQ ID NO: 12, 36 or 38; or a sequence having at least 50% identity thereto.
14. The method of claim 13, wherein said 2-hydroxyglutaryl-CoA dehydratase is from C. symbiosum] while said 2-hydroxyglutarate dehydrogenase; said glutaconate
CoA transferase and said activator protein are from A. fermentans.
15. The method as claimed in any of the preceding claims, wherein said proteins are each encoded by a nucleic acid sequence, which is adapted to the codon usage of said microorganism having the ability to produce said 2-oxo-dicarboxylic acid of formula II.
16. The method as claimed in any of the preceding claims, wherein said proteins are encoded by nucleic acid sequences contained in one or more expression vectors.
17. The method as claimed in any of the preceding claims, wherein at least one of said co-expressed proteins is heterologous to said recombinant microorganism.
18. The method as claimed in any of the preceding claims, wherein a compound of formula I is produced, wherein X is selected from CH2, C2H4, CH=CH; CH=C(OH).
19. An expression cassette, comprising a combination of at least two different nucleic acid sequences each encoding an enzyme or protein as defined in one of the claims 1 to 17, which sequences are operatively linked to at least one regulatory nucleic acid sequence.
20. A recombinant vector, comprising at least one expression cassette as claimed in claim 19.
21. A recombinant prokaryotic or eukaryotic host, transformed with at least one vector as claimed in claim 20.
22. The recombinant host of claim 21 having the ability to produce a 2-oxo- dicarboxylic acid compound of formula (II), which is converted to a compound of formula (I) upon expression of said expression products as encoded by said at least one vector.
23. The host of claim 22, which is a recombinant strain of a bacterium of the genus Escherichia.
24. A method of preparing a polyamide, which method comprises a) preparing a mono-unsaturated dicarboxylic acid compounds of the general formula (I) as defined above a by method of anyone of claims 1 to 18; b) isolating said compound optionally followed by hydrogenation in order to remove the C=C-double bond; and c) polymerizing said compound as obtained according to step b), with at least one suitable polyvalent amine monomer
25. The method of claim 24, wherein the polyamine is a di-amine, a tri-amine or a mixture thereof.
26. A method of preparing a polyester, which method comprises a) preparing a mono-unsaturated dicarboxylic acid compounds of the general formula (I) as defined above a by method of anyone of claims 1 to 18; b) isolating said compound optionally followed by hydrogenation in order to remove the C=C-double bond; and c) polymerizing said compound as obtained according to step b), with at least one suitable polyvalent alcohol.
27. A method of preparing a polymer, which method comprises a) preparing a mono-unsaturated dicarboxylic acid compounds of the general formula (I) as defined above a by method of anyone of claims 1 to 18; b) isolating said compound; and c) polymerizing said compound as obtained according to step b), with at least one suitable unsaturated polymerizable monomer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10700416A EP2387614A2 (en) | 2009-01-15 | 2010-01-15 | Method for the production of glutaconate |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09150669 | 2009-01-15 | ||
EP10700416A EP2387614A2 (en) | 2009-01-15 | 2010-01-15 | Method for the production of glutaconate |
PCT/EP2010/050475 WO2010081885A2 (en) | 2009-01-15 | 2010-01-15 | Method for the production of glutaconate |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2387614A2 true EP2387614A2 (en) | 2011-11-23 |
Family
ID=42340145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10700416A Withdrawn EP2387614A2 (en) | 2009-01-15 | 2010-01-15 | Method for the production of glutaconate |
Country Status (5)
Country | Link |
---|---|
US (1) | US8778645B2 (en) |
EP (1) | EP2387614A2 (en) |
JP (1) | JP5921194B2 (en) |
CN (1) | CN102782144B (en) |
WO (1) | WO2010081885A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2820141B1 (en) | 2012-02-29 | 2018-04-11 | Duke University | Novel oxidoreductases for enantioselective reactions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58165794A (en) * | 1982-03-26 | 1983-09-30 | Baiorisaac Center:Kk | Production of unsaturated dicarboxylic acid utilizing microorganism |
JPS61280289A (en) * | 1985-06-06 | 1986-12-10 | Nippon Kayaku Co Ltd | Production of 3-methylglutaconic acid |
FR2921363B1 (en) * | 2007-09-20 | 2009-11-06 | Arkema France | PROCESSES FOR THE SYNTHESIS OF FATTY DIACIDES BY METATHESIS OF UNSATURATED DIACIDS OBTAINED BY FERMENTATION OF NATURAL FATTY ACIDS |
DE102007048625B4 (en) * | 2007-10-01 | 2011-11-10 | Insilico Biotechnology Ag | Biotechnological production of crotonic acid |
-
2010
- 2010-01-15 WO PCT/EP2010/050475 patent/WO2010081885A2/en active Application Filing
- 2010-01-15 US US13/144,616 patent/US8778645B2/en not_active Expired - Fee Related
- 2010-01-15 JP JP2011545748A patent/JP5921194B2/en not_active Expired - Fee Related
- 2010-01-15 EP EP10700416A patent/EP2387614A2/en not_active Withdrawn
- 2010-01-15 CN CN201080011703.4A patent/CN102782144B/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
ANUTTHAMAN PARTHASARATHY ET AL: "Substrate Specificity of 2-Hydroxyglutaryl-CoA Dehydratase from Clostridium symbiosum : Toward a Bio-Based Production of Adipic Acid", BIOCHEMISTRY, vol. 50, no. 17, 3 May 2011 (2011-05-03), pages 3540 - 3550, XP055134345, ISSN: 0006-2960, DOI: 10.1021/bi1020056 * |
See also references of WO2010081885A2 * |
Also Published As
Publication number | Publication date |
---|---|
CN102782144A (en) | 2012-11-14 |
WO2010081885A3 (en) | 2011-01-13 |
JP5921194B2 (en) | 2016-05-24 |
US8778645B2 (en) | 2014-07-15 |
US20120021472A1 (en) | 2012-01-26 |
JP2012514990A (en) | 2012-07-05 |
WO2010081885A2 (en) | 2010-07-22 |
CN102782144B (en) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8771998B2 (en) | Process for the production of gamma-aminobutyric acid | |
KR102394701B1 (en) | 7-beta-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid | |
AU2009230728B2 (en) | Novel 12 alpha-hydroxysteroid dehydrogenases, production and use thereof | |
US10179923B2 (en) | Method for biocatalytically cyclizing geranyllinalool and cyclization products thereby obtained | |
JP7507739B2 (en) | Enzymatic cyclization of homofarnesylic acid. | |
CN110325646B (en) | Process for preparing (3E, 7E) -Gao Fani acid or (3E, 7E) -Gao Fani acid esters | |
US9187771B2 (en) | Phenylpyruvate reductase and method for manufacturing optically-active phenyllactic acid and 4-hydroxyl-phenyllactic acid using same enzyme | |
AU2009211870B2 (en) | Method for the production of dipicolinate | |
JP6509215B2 (en) | Genetic engineering of Pseudomonas putida KT 2440 for rapid and high yield production of vanillin from ferulic acid | |
US20120123155A1 (en) | Biocatalyst for catalytic hydroamination | |
US20220042051A1 (en) | Lipoxygenase-catalyzed production of unsaturated c10-aldehydes from polyunsatrurated fatty acids | |
US8778645B2 (en) | Method for the production of glutaconate | |
EP2706118A1 (en) | Method for the production of primary amines | |
EP2280075A1 (en) | Biocatalyst for catalytic hydroamination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110816 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20150130 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180801 |